US20060039993A1 - Retinal cell grafts and instrument for implanting - Google Patents
Retinal cell grafts and instrument for implanting Download PDFInfo
- Publication number
- US20060039993A1 US20060039993A1 US11/171,876 US17187605A US2006039993A1 US 20060039993 A1 US20060039993 A1 US 20060039993A1 US 17187605 A US17187605 A US 17187605A US 2006039993 A1 US2006039993 A1 US 2006039993A1
- Authority
- US
- United States
- Prior art keywords
- retina
- cells
- tube
- instrument
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002207 retinal effect Effects 0.000 title claims abstract description 46
- 238000002955 isolation Methods 0.000 claims abstract description 10
- 210000001525 retina Anatomy 0.000 claims description 201
- 210000004027 cell Anatomy 0.000 claims description 105
- 210000000608 photoreceptor cell Anatomy 0.000 claims description 29
- 230000008520 organization Effects 0.000 claims description 24
- 239000007943 implant Substances 0.000 claims description 14
- 238000002513 implantation Methods 0.000 claims description 6
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 2
- 239000012056 semi-solid material Substances 0.000 claims 2
- 239000011343 solid material Substances 0.000 claims 2
- 108091008695 photoreceptors Proteins 0.000 abstract description 177
- 210000001519 tissue Anatomy 0.000 abstract description 79
- 238000000034 method Methods 0.000 abstract description 60
- 210000003583 retinal pigment epithelium Anatomy 0.000 abstract description 31
- 238000001356 surgical procedure Methods 0.000 abstract description 7
- 238000002054 transplantation Methods 0.000 description 44
- 108010010803 Gelatin Proteins 0.000 description 34
- 239000008273 gelatin Substances 0.000 description 34
- 229920000159 gelatin Polymers 0.000 description 34
- 235000019322 gelatine Nutrition 0.000 description 34
- 235000011852 gelatine desserts Nutrition 0.000 description 34
- 239000000758 substrate Substances 0.000 description 28
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 25
- 241000700159 Rattus Species 0.000 description 25
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 24
- 210000003850 cellular structure Anatomy 0.000 description 22
- 230000001537 neural effect Effects 0.000 description 20
- 102000010175 Opsin Human genes 0.000 description 19
- 108050001704 Opsin Proteins 0.000 description 19
- 238000013459 approach Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000012530 fluid Substances 0.000 description 15
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 210000000981 epithelium Anatomy 0.000 description 10
- 230000001179 pupillary effect Effects 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 210000003161 choroid Anatomy 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 210000005056 cell body Anatomy 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 230000011514 reflex Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- 238000005286 illumination Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000004913 activation Effects 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 238000001000 micrograph Methods 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 208000003098 Ganglion Cysts Diseases 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 208000005400 Synovial Cyst Diseases 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000225 synapse Anatomy 0.000 description 5
- 241000288906 Primates Species 0.000 description 4
- 241000278713 Theora Species 0.000 description 4
- 210000003050 axon Anatomy 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 229930003347 Atropine Natural products 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
- 206010038848 Retinal detachment Diseases 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 atropine Drugs 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 230000004264 retinal detachment Effects 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010061431 Glial scar Diseases 0.000 description 2
- 206010018341 Gliosis Diseases 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 2
- 229950006874 kainic acid Drugs 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000005157 neural retina Anatomy 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 230000016732 phototransduction Effects 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 229920003319 Araldite® Polymers 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 210000000411 amacrine cell Anatomy 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- JVXZRNYCRFIEGV-UHFFFAOYSA-M dilC18(3) dye Chemical compound [O-]Cl(=O)(=O)=O.CC1(C)C2=CC=CC=C2N(CCCCCCCCCCCCCCCCCC)C1=CC=CC1=[N+](CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2C1(C)C JVXZRNYCRFIEGV-UHFFFAOYSA-M 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 201000006321 fundus dystrophy Diseases 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 238000011327 histological measurement Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004439 pupillary reactions Effects 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000010246 ultrastructural analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/383—Nerve cells, e.g. dendritic cells, Schwann cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
- A61L27/3891—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types as distinct cell layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00969—Surgical instruments, devices or methods, e.g. tourniquets used for transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M2025/0042—Microcatheters, cannula or the like having outside diameters around 1 mm or less
Definitions
- the instrument 30 does not include a lumen 42 , the retina is detached by the walls of the surgical instrument as it is advanced under the retina and into the subretinal space to the posterior pole 76 of the eye.
- the graft comprising a photoreceptor layer attached to the gelatin substrate is then transplanted by moving the tube 32 in a direction away from the eye while keeping the plunger 40 stationary.
- the plunger 40 is carefully withdrawn out of the eye and the edges of the corneal incision are abutted after removal to allow rapid, sutureless healing.
- Retinal reattachment occurs rapidly and the photoreceptor sheet is held in place in a sandwich-like arrangement between the retina and the underlying eye tissues.
- the incision may require suturing.
- RET-P1 a monoclonal antibody specific for opsin
- any cell showing labeling for opsin was, therefore, identified as a photoreceptor.
- FIGS. 24 and 25 C the transplanted cells stain intensely for opsin whereas other retinal cells are unstained. Positive staining for opsin not only identifies these cells as photoreceptors but indicates that these cells are still capable of producing the protein moiety of visual pigment.
- Retina adjacent to the region of the transplant shows only a few isolated photoreceptor cell bodies ( FIG. 23 ) that do not stain for opsin ( FIG. 24 ) suggesting that they are cones. Their lack of opsin staining, as well as their location and appearance in H & E-stained material, confirms that these cells are the host's residual photoreceptors ( FIG. 23 ).
- the transplantation technique was adapted to the smaller size of the mouse eye. This modification allowed sheets of intact outernuclear layer to be transplanted to the subretinal space of the mouse eye.
- Neonatal (8 days old) photoreceptors were transplanted from rd control mice to the subretinal space of adult rd mice. Survival times were for 2 weeks to 3 months. At all survival times, it was found that the transplanted photoreceptors survived, becoming physically attached to the outer portion of the host retina and stained positive for opsin. In addition, the host retina became reattached to the pigment epithelium.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Cardiology (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
Surgical instruments, surgical techniques, retinal cell grafts, retinal cell and tissue isolation techniques, and a method for transplanting retinal cells, including photoreceptors, and/or retinal pigment epithelium, with the cells in the isolated tissue having their normal cell to cell configuration are disclosed.
Description
- This application is a divisional of Ser. No. 10/323,958, filed Dec. 17, 2002, which is a divisional of Ser. No. 09/411,122 filed Oct. 4, 1999, now U.S. Pat. No. 6,579,256, which is a divisional of Ser. No. 08/322,735, filed Oct. 13, 1994, now U.S. Pat. No. 5,962,027, which is a continuation of Ser. No. 07/566,996 filed Aug. 13, 1990, abandoned, which is a continuation in part of Ser. No. 07/394,377, filed Aug. 14, 1989, abandoned, all of which are incorporated by reference as if reproduced in full below.
- The present invention relates in general to surgical instruments, surgical techniques, and cell and tissue isolation techniques. More particularly, the present invention is directed to a surgical tool for transplanting retinal cells, epithelium and choroidea within their normal planar configuration, a graft for transplantation to the subretinal region of the eye, a method for preparing such grafts for transplantation, and a method for reconstructing dystrophic retinas, retinal pigment epithelial layers and choroids.
- The retina is the sensory epithelial surface that lines the posterior aspect of the eye, receives the image formed by the lens, transduces this image into neural impulses and conveys this information to the brain by the optic nerve. The retina comprises a number of layers, namely, the ganglion cell layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, photoreceptor inner segments and outer segments. The outer nuclear layer comprises the cell bodies of the photoreceptor cells with the inner and outer segments being extensions of the cell bodies.
- The choroid is a vascular membrane containing large branched pigment cells that lies between the retina and the sclerotic coat of the vertebrate eye. Immediately between the choroid and the retina is the retinal pigment epithelium which forms an intimate structural and functional relationship with the photoreceptor cells.
- Several forms of blindness are primarily related to the loss of photoreceptor cells caused by defects in the retina, retinal pigment epithelium, choroid or possibly other factors (e.g. intense light, retinal detachment, intraocular bleeding). In several retinal degenerative diseases select populations of cells are lost. Specifically, in macular degeneration and retinitis pigmentosa retinal photoreceptors degenerate while other cells in the retina as well as the retina's central connections are maintained. In an effort to recover what was previously thought to be an irreparably injured retina, researchers have suggested various forms of grafts and transplantation techniques, none of which constitute an effective manner for reconstructing a dystrophic retina.
- The transplantation of retinal cells to the eye can be traced to a report by Royo et al., Growth 23: 313-336 (1959) in which embryonic retina was transplanted to the anterior chamber of the maternal eye. A variety of cells were reported to survive, including photoreceptors. Subsequently del Cerro was able to repeat and extend these experiments (del Cerro et al., Invest. Ophthalmol. Vis. Sci. 26: 1182-1185, 1985). Soon afterward Turner, et al. Dev. Brain Res. 26:91-104 (1986) showed that neonatal retinal tissue could be transplanted into retinal wounds.
- In related studies, Simmons et al., Soc. Neurosci. Abstr. 10: 668 (1984) demonstrated that embryonic retina could be transplanted intracranially, survive, show considerable normal development, be able to innervate central structures, and activate these structures in a light-dependent fashion. Furthermore, these intracranial transplants could elicit light-dependent behavioral responses (pupillary reflex) that were mediated through the host's nervous system. Klassen et al., Exp. Neurol. 102: 102-108 (1988) and Klassen et al. Proc. Natl. Acad., Sci. USA 84:6958-6960 (1987).
- Li and Turner, Exp. Eye Res. 47:911 (1988) have proposed the transplantation of retinal pigment epithelium (RPE) into the subretinal space as a therapeutic approach in the RCS dystrophic rat to replace defective mutant RPE cells with their healthy wild-type counterparts. According to their approach, RPE were isolated from 6- to 8-day old black eyed rats and grafted into the subretinal space by using a lesion paradigm which penetrates through the sclera and choroid. A 1 μl injection of RPE (40,000-60,000 cells) was made at the incision site into the subretinal space by means of a 10 μl syringe to which was attached a 30 gauge needle. However, this method destroys the cellular polarity and native organization of the donor retinal pigment epithelium which is desirable for transplants.
- del Cerro, (del Cerro et al., Invest. Ophthalmol. Vis. Sci. 26: 1182-1185, 1985) reported a method for the transplantation of tissue strips into the anterior chamber or into the host retina. The strips were prepared by excising the neural retina from the donor eye. The retina was then cut into suitable tissue strips which were then injected into the appropriate location by means of a 30 gauge needle or micropipette with the width of the strip limited to the inner diameter of the needle (250 micrometers) and the length of the strip being less than 1 millimeter. While del Cerro reports that the intraocular transplantation of retinal strips can survive, he notes that the procedure has some definite limitations. For instance, his techniques do not allow for the replacement of just the missing cells (e.g. photoreceptors) but always include a mixture of retinal cells. Thus, with such a transplant appropriate reconstruction of the dystrophic retina that lacks a specific population of cells (e.g., photoreceptors) is not possible.
- del Cerro et al., Neurosci. Lett. 92: 21-26, 1988, also reported a procedure for the transplantation of dissociated neuroretinal cells. In this procedure, the donor retina is cut into small pieces, incubated in trypsin for 15 minutes, and triturated ii into a single cell suspension by aspirating it through a fine pulled pipette. Comparable to the Li and Turner approach discussed above, this procedure destroys the organized native structure of the transplant, including the donor outer nuclear layer; the strict organization of the photoreceptors with the outer segments directed toward the pigment epithelium and the synaptic terminals facing the outer plexiform layer are lost. Furthermore, no means of isolating and purifying any given population of retinal cells (e.g. photoreceptors) from other retinal cells was demonstrated.
- It is believed by the present inventor that it is necessary to maintain the photoreceptors in an organized outer nuclear layer structure in order to restore a reasonable degree of vision. This conclusion is based on the well known optical characteristics of photoreceptors (outer segments act as light guides) and clinical evidence showing that folds or similar, even minor disruptions in the retinal geometry can severely degrade visual acuity.
- Among the objects of the present invention, therefore, may be noted the provision of a method for preparation of a graft for use in the reconstruction of a dystrophic retina; the provision of such a method which conserves relatively large expanses of the tissue harvested from a donor eye; the provision of such a method in which the polarity and organization of the cells at the time of harvest are maintained in the graft; the provision of a graft for use in the reconstruction of a dystrophic retina; the provision of such a graft which facilitates regrowth of photoreceptor axons by maintaining the polar organization of the photoreceptor and the close proximity of their postsynaptic targets with the adjacent outer plexiform layer upon transplantation; the provision of a surgical tool for use in the transplantation method which allows appropriate retinotopic positioning and which protects photoreceptors or other grafted tissue from damage prior to and as the surgical device is positioned in the eye; and the provision of a method for transplantation of grafts to the subretinal area of an eye.
- Briefly, therefore, the present invention is directed to a method for the preparation of a graft for transplantation to the subretinal area of a host eye. The method comprises providing donor tissue and harvesting from that tissue a population of cells selected from retinal cells, epithelial tissue or choroidal tissue, the population of cells having the same organization and cellular polarity as is present in normal tissue of that type. The population of cells is laminated to a non-toxic and flexible composition which substantially dissolves at body temperature.
- The present invention is further directed to a method for the preparation of a graft comprising photoreceptor cell bodies for transplantation to the subretinal area of a host eye. The method comprises providing a donor retina containing a layer of photoreceptor cell bodies. The layer of photoreceptor cell bodies is isolated from at least one other layer of cells of the donor retina in a manner that maintains the layer of photoreceptor cell bodies in the same organization and cellular polarity as is present in normal tissue of that type.
- The present invention is further directed to a graft for transplantation to the subretinal area of a host eye. The graft comprises a laminate of a non-toxic and flexible composition which substantially dissolves at body temperature and a population of cells harvested from a donor eye, the population of cells being selected from retinal cells, epithelial tissue and choroidal tissue. The population of cells has the same organization and cellular polarity as is present in normal tissue of that type.
- The present invention is further directed to a graft for transplantation to the subretinal area of a host eye. The graft comprises a population of photoreceptor cell bodies harvested from a donor retina, the population of photoreceptor cell bodies having the same organization and cellular polarity as is present in normal tissue of that type, the graft having an essential absence of at least one layer of cells present in the donor retina.
- The present invention is further directed to a method for transplanting to the subretinal area of a host's eye a graft comprising a population of cells. The method comprises providing a graft comprising a population of cells selected from retinal cells isolated from at least one other layer of cells within the retina, epithelial tissue and choroidal tissue, the population of cells being maintained in the same organization and t cellular polarity as is present in normal tissue of that type. An incision is made through the host's eye, the retina is at least partially detached to permit access to the subretinal area and the graft is positioned in the accessed subretinal area.
- The present invention is further directed to an instrument for the implantation of an intact planar cellular structure between the retina and supporting tissues in an eye. The instrument comprises an elongate supporting platform for holding the planar cellular structure. The platform has a distal end for insertion into an eye, and a proximal end. The distal edge of the platform is convexly curved for facilitating the insertion of the platform into the eye and the advancement of the platform between the retina and the supporting tissues. The instrument has a side rail on each side of the platform for retaining the planar cellular structure on the platform, the distal ends of the side rails being rounded, and the distal portions of the side rails tapering toward the distal end of the platform to facilitate the insertion of the instrument between the retina and the supporting tissue.
- The present invention is further directed to an instrument for the implantation of an intact planar cellular structure between the retina and supporting tissues in an eye. The instrument comprises an elongate tube, having a flat, wide cross-section, with a top, a bottom for supporting the planar cellular structure, and opposing sides. The tube has a beveled distal edge facilitating the insertion of the tube into the eye and the advancement of the tube between the retina and the supporting tissues. The instrument also comprises plunger means for ejecting a planar cellular structure from the distal end of the tube.
- The present invention is further directed to a kit for transplantation of a graft to the subretinal area of a host eye. The kit contains a graft comprising a population of cells selected from retinal cells, epithelial tissue and choroidal tissue, the population of cells being maintained in the same organization and cellular polarity as is present in normal tissue of that type. The kit additionally contains a surgical instrument comprising an elongate tube, having a flat, wide cross-section, with a top, a bottom for supporting the planar cellular structure, and opposing sides. The tube has a beveled distal edge facilitating the insertion of the tube into the eye and the advancement of the tube between the retina and the supporting tissues. The surgical instrument also comprises plunger means for ejecting a planar cellular structure from the distal end of the tube.
- Other objects and features of the invention will be in part apparent and in part pointed out hereinafter.
-
FIG. 1 is a photograph of a cryostat section of normal rat retina as set forth in Example 1; -
FIG. 2 is a photograph of a blinded rat retina following constant illumination as set forth in Example 1; -
FIG. 3 is a schematic of a donor retina; -
FIG. 4 is a schematic of a flattened retina; -
FIG. 5 is a schematic of a flattened retina mounted to a substrate; -
FIG. 6 is a schematic of a sectioned retina mounted to a substrate; -
FIG. 7 is a schematic of a laminate comprising a retina section on a supporting, stabilizing substrate; -
FIG. 8 is a schematic top plan view of the laminate ofFIG. 7 , showing a graft (dashed lines) comprising a photoreceptor cell layer and a supporting, stabilizing substrate; -
FIG. 9 is a perspective view of a first embodiment of an instrument adapted for implanting an intact planar cellular structure between the retina and supporting tissues in an eye; -
FIG. 10 is a side elevation view of a second embodiment of an instrument adapted for implanting an intact planar cellular structure between the retina and supporting tissues in an eye, with the plunger in its retracted position, and with portions broken away to show detail; -
FIG. 11 is a top plan view of the instrument shown inFIG. 10 ; -
FIG. 12 is a side elevation view of the instrument of the second embodiment, with the plunger in its extended position, and with portions broken away to show detail; -
FIG. 13 is a top plan view of the instrument shown inFIG. 12 ; -
FIG. 14 is a partial longitudinal cross-sectional view of the instrument, showing part of a planar cellular structure loaded therein; -
FIG. 15 is a top plan view of a first alternative construction of the second embodiment; -
FIG. 16 is a top plan view of a second alternative construction of the second embodiment; -
FIG. 17 is a top plan view of a third alternative construction of the second embodiment; and -
FIG. 18 is a top plan view of the second embodiment, showing an alternative plunger means. -
FIG. 19 is a horizontal section through an eye illustrating a trans-corneal surgical approach; -
FIG. 20 is a horizontal section through an eye illustrating a trans-choroidal and scleral surgical approach; -
FIG. 21 is a photograph of transplanted photoreceptors as set forth in Example 1; -
FIG. 22 is a photograph of donor photoreceptors transplanted at the posterior pole of the recipient eye as set forth in Example 1; -
FIG. 23 shows the interface between the transplant and the adjacent retina devoid of outer nuclear layer as set forth in Example 1; -
FIG. 24 is a photograph illustrating FITC fluorescent micrograph of antibody Ret P-1 specific for opsin as set forth in Example 1; -
FIG. 25 is a series of photograph panels illustrating in A, transplanted photoreceptors attached to recipient or host retina, in B, fluorescent micrograph showing transplanted cells showing Dil fluorescence, identifying them as transplanted tissue, and in C, a micrograph illustrating FITC fluorescence of antibody specific for opsin as set forth in Example 1; -
FIG. 26 comprises two micrograph panels, in A, transplant of nature rat photoreceptors to adult light damaged recipient or host, and in B, transplant of human photoreceptor from adult donor to adult light damaged rat host or recipient as set forth in Example 4; -
FIGS. 27 a, 27 b, 27 c, 27 d are 14C 2-deoxyglucose (2DG) autoradiographs, DYST-dystrophic, TRANS-transplant as set forth in Example 5; and -
FIGS. 28 a, 28 b, 28 c and 28 d are a series of photographs showing pupillary reflex to light as set forth in Example 9. - As used herein, the term “donor” shall mean the same or different organism relative to the host and the term “donor tissue” shall mean tissue harvested from the same or different organism relative to the host.
- Several forms of blindness such as retinitis pigmentosa, retinal detachment, macular degeneration, and light exposure-related blindness, are primarily related to the loss of the photoreceptors in the eye. However, destruction of the photoreceptors does not necessarily lead to the loss of the remaining retina or axons that connect the retina to the brain. Surprisingly, it has been discovered that some degree of vision can be restored by replacing damaged photoreceptors with photoreceptors harvested from a donor and which are maintained in their original organization and cellular polarity.
-
FIG. 1 is a photograph of a cryostat section of normal rat retina.FIG. 2 is a photograph of a cryostat section of a rat retina following constant illumination which destroys the photoreceptor (outer nuclear) layer while leaving other retinal layers and cells largely intact. In these and subsequent figures, the retina or layers thereof, e.g., the ganglion cell layer (“G”), inner plexiform layer (“IPL”), inner nuclear layer (“INL”), outer plexiform layer (“OPL”), outer nuclear layer (“ONL”), inner segments (“IS”), outer segments (“OS”), and retinal pigment epithelium (“RPE”), are shown, respectively, from top to bottom. - Referring now to
FIG. 3 , a graft comprising photoreceptor cells is prepared in accordance with a method of the present invention by removing adonor retina 50 comprising inner retina layers 52 andphotoreceptor layer 54 from a donor eye. Thedonor retina 50 is flattened (FIG. 4 ) by making a plurality of cuts through the retina from locations near the center of the retina to the outer edges thereof (seeFIG. 8 ). Cuts can be made in other directions if necessary. - As shown in
FIG. 5 , the flattenedretina 56 is placed with thephotoreceptor side 54 down on agelatin slab 58 which has been surfaced so as to provide aflat surface 60 that is parallel to the blade of a vibratome apparatus. Thegelatin slab 58 is secured to a conventional vibratome chuck of the vibratome apparatus. Molten four to five per cent gelatin solution is deposited adjacent the flattened retina/gelatin surface interface 61 and is drawn by capillary action under the flattened retina causing the flattened retina to float upon thegelatin slab 58. Excess molten gelatin is promptly removed and the floating flattened retina is then cooled to approximately 4° C. with ice-cold Ringer's solution that surrounds the gelatin block to cause the molten gelatin to gel and hereby coat the bottom surface of the flattened retina and adhere it to the gelatin block. - As shown in
FIG. 6 , theinner retina portion 52 is sectioned from the top down at approximately 20 to 50 millimicrons until thephotoreceptor layer 54 is reached, thereby isolating the photoreceptor layer from the inner layers of the retina, i.e., the ganglion cell layer, inner plexiform layer, inner nuclear layer, and outer plexiform layer. When the photoreceptor layer is reached, the vibratome stage is advanced and a section from approximately 200 to 300 millimicrons thick obtained as shown inFIG. 7 . The thickness of this section is sufficient to undercut the photoreceptor and form a laminate 62 consisting of a layer of photoreceptor cells and the gelatin adhered thereto. - As shown in
FIG. 8 , the laminate 62 is cut vertically along the dashed lines to create agraft 63 having a size appropriate for transplantation. The surface of the graft should have a surface area greater than about 1 square millimeter, preferably greater than 2 square millimeters, and most preferably greater than 4 square millimeters or as large as may be practically handled. Thus constructed, the graft may subtend a considerable extent of the retinal surface. - The gelatin substrate adds mechanical strength and stability to the easily damaged photoreceptor layer. As a result, the flattened retinal tissue is less likely to be damaged and is more easily manipulated during the transplantation procedure.
- Gelatin is presently preferred as a substrate because of its flexibility, apparent lack of toxicity to neural tissue and ability to dissolve at body temperature.
- However, other compositions such as ager or agarose which also have the desirable characteristics of gelatin may be substituted. Significantly, gelatin has not been found to interfere with tissue growth or post-transplant interaction between the graft and the underlying retinal pigment epithelium.
- Gelatin is presently preferred as an adhesive to laminate the retinal tissue to the substrate. However, other compositions, including lectins such as concanavalin A, wheat germ agglutin, or photoreactive reagents which gel or solidify upon exposure to light and which also have the desirable characteristics of gelatin may be substituted.
- Advantageously, the gelatin or other substrate may additionally serve as a carrier for any of a number of trophic factors such as fibroblast growth factor, pharmacologic agents including immunosuppressants such as cyclosporin A, anti-inflamation agents such as dexamethasone, anti-angiogenic factors, anti-glial agents, and anti-mitotic factors. Upon dissolution of the substrate, the factor or agent becomes available to impart the desired effect upon the surrounding tissue. The dosage can be determined by established experimental techniques. The substrate may contain biodegradable polymers to act as slow release agents for pharmacologic substances that may be included in the substrate.
- The thickness of the graft comprising the sectioned flattened retinal tissue and the substrate as discussed above is only approximate and will vary as donor material varies. In addition, sectioning may be facilitated and vibratome thickness further calibrated from histological measurements of the thickness of the retina, thereby providing further guides to sectioning depth. Appropriate sectioning thicknesses or depth may be further determined by microscopic examination and observation of the sections.
- As an alternative to mechanical, e.g., microtome, sectioning, the donor retina may be chemically sectioned. Specifically it is known that neurotoxic agents such as kainic acid are toxic to cells in all retinal layers except the photoreceptor layer (i.e., kainic acid does not damage photoreceptor cells). Therefore, if the donor retina is treated with an appropriate neurotoxic agent, the photoreceptor layer can be isolated. This technique has the advantage of maintaining the retinal MUller cells (which are not killed by kainic treatment) with the photoreceptor cells. Since it is known that MUller cells help maintain photoreceptor cells (both biochemically and structurally), the isolation of MUller cells along with the photoreceptor cells could be advantageous.
- If desired, the graft may additionally contain the retinal pigment epithelial cells. Because the RPE is tenuously adherent to the retina, mechanical detachment of the retina from a donor eye ordinarily will cause the RPE to separate from the retina and remain attached to the choroid. However, through the use of enzymatic techniques such as those described in Mayerson et al., Invest. Opthalmol. Vis, Sci. 25: 1599-1609, 1985, the retina can be separated from the donor eye with the RPE attached. In accordance with the present invention, grafts comprising the choroid may additionally be prepared. To do so, the choroid is stripped off of the scleral lining of the eye (with or without the RPE attached), and flattened by making radial cuts. The donor choroid may then be adhered to a substrate as previously described for the photoreceptor cells and/or combined with a photoreceptor layer which has been prepared as described above to form a laminate comprising a photoreceptor layer adhered to a substrate, a RPE layer and a choroidal layer.
- Referring again to the Figures there is shown preferred embodiments for the surgical instruments of this invention. The surgical instruments are described in connection with a photoreceptor isolation and transplantation method. The surgical instruments and methods of this invention are particularly adapted for isolation and transplantation of an intact sheet of cells from a donor retina to a recipient retina and are characterized by the maintenance of cell organization of the transplanted tissue layer.
- A first embodiment of an instrument for implanting an intact planar cellular structure between the retina and supporting tissues in an eye is indicated generally as 10 in
FIG. 9 . Theinstrument 10 may be made from acrylic, or some other suitable material that is flexible and sterilizable. Theinstrument 10 comprises an elongate platform 11 for holding the planar cellular structure. The platform 11 has adistal end 16 for insertion into the eye of the recipient, and aproximal end 18. As shown and described herein the platform 11 is approximately 2 to 10 centimeters long, which is an appropriate length for making implants in rodents and lower primates. The platform 11 must be sufficiently long to extend into the eye, between the retina and the supporting tissue, and thus different platform lengths may be used, depending upon the procedure being employed and upon the recipient. As shown and described herein the platform is approximately 2.5 millimeters wide, which is sufficiently wide for making implants in rodents and lower primates. The platform 11 must be sufficiently wide to carry and intact cellular structure for implanting, and thus different platform widths may be used, depending upon the recipient. - As shown in
FIG. 9 , the edge 11 a of the platform 11 at thedistal end 16 is preferably convexly curved to facilitate both the insertion of theinstrument 10 into the eye, and the advancement of the instrument between the retina and the supporting tissue to temporarily detach the retina, with a minimum of trauma. The platform 11 is preferably concavely curved (with respect to the top surface of the platform 11) along its longitudinal axis from thedistal end 16 to theproximal end 18. The curvature of the platform 11 facilitates the manipulation of theinstrument 10 within the eye, particularly the manipulation of the instrument between the retina and the supporting tissue on the curved walls of the eye. The radius of the curvature of the platform 11 will depend upon the procedure and the recipient. - The platform 11 has side rails 12 and 14 on opposite sides for retaining the planar cellular structure on the platform. As shown in
FIG. 9 , the distal portions 12 a and 14 a of the side rails taper from a point intermediate the distal and proximal ends of the side rails toward their distal ends. The distal ends of the side rails terminate in smoothly curved ends 12 b and 14 b, which are proximal of thedistal end 16 of the platform. The offset of the distal ends of the rails, together with their rounded configuration facilitates the insertion of the instrument into the eye and the advancement of the instrument between the retina and the supporting tissue. As shown and described herein, the proximal portions of the side rails 12 and 14 are approximately 1 millimeter high, while the distal portions 12 a and 14 a taper to about 0.5 millimeters. The height of the side rails is made as small as possible, but they must be slightly greater than the thickness of the planar cell structure and the supporting substrate, and thus may vary depending on the donor and the type of implantation being made (i.e., how many cell layers are being implanted and thickness of the substrate). - A second embodiment of an instrument for implanting an intact planar cellular structure between the retina and supporting tissues in an eye is indicated generally as 30 in
FIGS. 10-14 , and 18. Theinstrument 30 may be made from polyethylene, or some other suitable material that is flexible and sterilizable. For example, the instrument might be made of silicone rubber or silastic. Theinstrument 30 comprises anelongate tube 32 having a flat, wide cross-section, with a top 32 a, a bottom 32 b for supporting the planar cellular structure, and opposingsides tube 32 has adistal end 34 for insertion into the eye, and aproximal end 36. Thedistal end 34 of thetube 32 is open for the discharge of the planar cellular structure. Theinstrument 30 of the second embodiment is preferable to theinstrument 10 of the first embodiment in at least one respect because thetube 32 has a top 32 a which provides better protection for the planar cellular structure to be implanted than the open platform 11. - As shown and described herein the
tube 32 is approximately 3.5 centimeters long, which is an appropriate length for making implants in rodents and lower primates. Thetube 32 must be sufficiently long to extend into the eye, between the retina and the supporting tissue, and thus the different tube lengths may be used, depending upon the procedure being employed and upon the recipient. As shown and described herein the tube is approximately 2.5 centimeters wide, which is sufficiently wide for making implants in rodents and lower primates. The tube must be sufficiently wide to carry an intact cellular structure for implanting, and thus different tube widths may be used, depending upon the recipient. As shown and described herein, thesides - The
distal end 34 of the tube can be beveled to facilitate both the insertion of the tube into the eye, and the advancement of the tube between the retina and the supporting tissues, with a minimum of trauma. The end is preferably beveled at about 45°, from the top 32 a to the bottom 32 b. As shown inFIGS. 10 and 12 , thedistal end 34 of thetube 32 is also preferably raked transversely across the tube (i.e. fromside 32 c to 32 d) toward the proximal end. The rake angle is preferably about 45°. The raked distal end also facilitates the insertion of the tube into the eye, and the advancement of the tube between the retina and the supporting tissue. Moreover, raking the distal end eliminates a sharp corner that could damage tissue. - The
tube 32 is preferably concavely curved along its longitudinal axis from thedistal end 34 to theproximal end 36, so that the top 32 a is on the inside of the curve, and the bottom 32 b is on the outside of the curve. The curvature of the tube facilitates the manipulation of theinstrument 30 within the eye, particularly the manipulation of the instrument between the retina and the supporting tissue on the curved walls of the eye. The radius of the curvature of the tube will depend on the procedure and on the recipient. - The
instrument 30 also comprises plunger means. As shown inFIGS. 10-14 , the plunger means is preferably aflat plunger 40 slidably received in the tube so that relative sliding motion between thetube 32 and theplunger 40 urges a planar cellular structure that is in the tube out the distal end of the tube. Theplunger 40 may be made of polymethylmethacrylate. The proximal end of theplunger 40 projects a sufficient amount from the proximal end of thetube 32 that the end of the plunger can be manipulated even when the distal portion of the tube is in an eye. The preferred method of operating theinstrument 30 is that once the distal end of the tube is properly located within the subretinal area, theplunger 40 is held in place as thetube 32 is gradually withdrawn to eject the cellular structure. - Alternatively, as shown in
FIG. 18 , the plunger means may comprise means for applying hydraulic pressure on the contents of the tube. In this case theproximal end 36 of thetube 32 is connected to aline 41 connected to a source of fluid under pressure. Fluid can be selectively supplied via theline 41 to the proximal end of the tube, to displace the contents of the tube. The fluid may be viscous, for example a 2% carboxymethylcellulose, or non-viscous. Particularly in the later case, it may be desirable to have ablock 43 of gelatin or some other substance in the tube to act as a mechanical plunger and to separate the fluid from the cell structure being implanted. Gelatin is satisfactory because it is a semi-solid, and because it will dissolve harmlessly if it is ejected from the tube. - As shown in
FIGS. 10-13 , theinstrument 30 preferably also includes alumen 42, extending generally parallel with thetube 32. As used herein, lumen refers to any tube-like vessel, whether separately provided or formed as a passageway in another structure. Thelumen 42 is attached to one of the sides of thetube 32, and preferablyside 32 c so that the distal end of the tube rakes away from the lumen. Thelumen 42 has adistal end 44 generally adjacent the distal end of the tube, and preferably slightly advanced relative to the distal end of the tube. Theproximal end 46 is remote from the distal end, and may be provided with aconnector 48 for connection with a source of fluid under pressure. Thus thelumen 42 can eject a stream of fluid from itsdistal end 44 which creates a fluid space ahead of the instrument, which helps separate or detach the retina from the supporting tissue as the instrument is advanced. The fluid may be a saline solution, or some other fluid that will not harm the delicate eye tissues. Various substances, such as anti-oxidants, anti-inflammatories, anti-mitotic agents and local anesthetics can be provided in the fluid for treatment of the eye or implanted tissue. - The raked distal end of the
tube 32 follows generally in the path opened by the fluid, thus minimizing direct contact of the instrument and the eye tissue. The distal end of the lumen may be beveled to facilitate the advancement of the instrument, particularly at times when fluid is not being ejected from the lumen. The end is preferably beveled at about 45°. Of course, rather than provide aseparate lumen 42, the lumen could be formed integrally in the walls of thetube 32. - A first alternate construction of
instrument 30 is indicated as 30A inFIG. 15 . Theinstrument 30A is very similar in construction toinstrument 30, and corresponding parts are identified with corresponding reference numerals. However, unlikeinstrument 30, theinstrument 30A includes afiber optic filament 64 extending generally parallel withlumen 42, and positioned between thelumen 42 and thetube 32. Thefiber optic filament 64 facilitates the manipulation of the instrument and the proper placement of the implant in two ways: a light source can be provided at the proximal end of the fiber optic filament so that the filament provides light at the distal end of the instrument, to facilitate the visual observation procedure through the pupil. Alternatively, a lens could be provided at the proximal end of the fiber optic filament so that the filament can also be used for direct observation at the distal end of the instrument. - Additionally, the fiber optic filament could allow for laser-light cautery to control subretinal bleeding. Of course, rather than provide a separate
fiber optic filament 64, fiber optic filaments could be incorporated into the walls of thetube 32 or thelumen 42. - A second alternative construction of
instrument 30 is indicated as 30B inFIG. 16 . Theinstrument 30B is very similar in construction toinstrument 30, and corresponding parts are identified with corresponding reference numerals. However, unlikeinstrument 30, theinstrument 30B includes alumen 66 extending generally parallel withlumen 42, and positioned between thelumen 42 and thetube 32. Thelumen 66 allows for the aspiration of material from the distal end of the instrument. The proximal end of thelumen 66 can be connected to a source of suction, to remove excess fluid and debris. It is possible to incorporate thelumen 66 into the wall of thetube 32. - A third alternative construction of the
instrument 30 is indicated as 30C inFIG. 17 . The instrument 30C is very similar in construction toinstrument 30, and corresponding parts are identified with corresponding reference numerals. However, unlikeinstrument 30, the instrument 30C includes a pair of lead wires 65, terminating in anelectrode 67 at their distal ends. Theelectrode 67 allows for cauterization of blood vessels. The proximal ends of the leads 65 can be connected to a source of electrical power to seal broken blood vessels. It is possible to incorporate the leads 65 into the wall of thetube 32. - Of course, two or more of the features described with respect to the
alternate embodiments - To transplant the retinal cells, including photoreceptors, the host eye is prepared so as to reduce bleeding and surgical trauma. A transcorneal surgical approach to the subretinal space is one such approach and it will be understood that other surgical approaches, such as transscleral and choroidal may also be used. The preferred surgical approach in the rodent,
FIG. 19 , includes making a transverse incision 70 in acornea 72 of sufficient size so as to allow insertion of a surgical instrument illustrated schematically byreference characters instrument 10 is advanced under the iris, through thecornea 72 and to the ora serrata 74 as illustrated inFIG. 19 . The iris should be dilated for example, with topical atropine. When theinstrument 10 is used, it detaches the retina as it is advanced under the retina and into the sub-retinal space to theposterior pole 76 of the eye. - The channel defined by the side rails 12, 14 and the intermediate cell supporting platform provides for the graft comprising a
photoreceptor layer 54 attached to the gelatin substrate to be placed on theinstrument 10 and guided into the sub-retinal space, preferably with forceps or other suitable instruments. After positioning the photoreceptor layer at the desired transplant site, the gelatin is held in position with the forceps while the carrier is removed. The edges of the corneal incision are abutted after removal of the forceps to allow rapid, sutureless healing. The eye should be patched during recovery. - If the surgical instrument 30 (
FIGS. 10-14 , and 18) is used instead of theinstrument 10, the graft comprising intact generallyplanar sheet 54 of donor photoreceptors attached to thegelatin substrate 62 is drawn into theelongate tube 32. Theinstrument 30 is then inserted through an appropriate sized incision in the cornea and advanced under the iris. The iris will have been dilated, for example, with topical atropine. Theinstrument 30 is advanced to the ora serrata 74 of the host eye. If theinstrument 30 includes alumen 42, the retina is detached by the gentle force of a perfusate such as a saline-like fluid, carboxymethylcellulose, or 1-2% hyluronic acid ejected from thelumen 42. Advantageously, the fluid may additionally contain anti-oxidants, anti-inflammation agents, anesthetics or agents that slow the metabolic demand of the host retina. - If the
instrument 30 does not include alumen 42, the retina is detached by the walls of the surgical instrument as it is advanced under the retina and into the subretinal space to theposterior pole 76 of the eye. The graft comprising a photoreceptor layer attached to the gelatin substrate is then transplanted by moving thetube 32 in a direction away from the eye while keeping theplunger 40 stationary. Theplunger 40 is carefully withdrawn out of the eye and the edges of the corneal incision are abutted after removal to allow rapid, sutureless healing. Retinal reattachment occurs rapidly and the photoreceptor sheet is held in place in a sandwich-like arrangement between the retina and the underlying eye tissues. The incision may require suturing. -
FIG. 20 depicts a trans-choroidal and scleral surgical approach as an alternative to the transcorneal approached described above. Except for the point of entry, the surgical technique is essentially the same as outlined above. Nevertheless, the transcorneal approach is preferred because it has been found to reduce bleeding and surgical trauma. - A further surgical approach is to diathermize in the pars plana region to eliminate bleeding. The sclera is then incised and the choroidal and epithelial tissue is diathermized. The surgical tool is then inserted through the incision, the retina is intercepted at the ora serrata and the graft is deposited in the subretinal area otherwise as outlined elsewhere herein.
- In yet a further surgical approach, entry is gained through the pars plana area as outlined above and an incision is made in the retina adjacent to the retinal macula. The surgical tool is then inserted through the retinotomy and into the macular area.
- It is known that the retina does not necessarily undergo glial scar formation when it is damaged, unlike the adult central nervous system as disclosed by Bigami et al., Exp. Eye Res. 28:63-69, (1979), and McConnel et al., Brain Res. 241:362-365 (1982). McConnel et al. suggest that this characteristic lack of scar tissue contribute to a potential of retinal cells to regrow severed axons within the eye.
- In accordance with the present invention, it has recognized that regrowth of photoreceptor axons may be facilitated by the proximity of the post-synaptic targets of the photoreceptor within the adjacent outer plexiform layer. In addition, growth across substantial intervening neural or glial scar tissue is not necessary in order for transplanted photoreceptors to make appropriate connections with the recipient retina including neural connections.
- The following examples illustrates the invention.
- Experimental Animals
- Adult albino rats (Sprague-Dawley) were exposed to constant illumination averaging 1900 lux for 2 to 4 weeks as described in O'Steen, Exp. Neurol. 27:194 (1970).
- As shown in
FIG. 1 , this exposure destroys most photoreceptors, eliminating cells of the outer nuclear layer but leaving the remaining neural retina intact. Photoreceptors for transplantation were taken from 8-day-old normal rats of the same strain that had been maintained under colony room illumination (10-20 lux) on a 12 hr/12 hr light/dark cycle. Experimental animals were anesthesized with ketamine and sodium pentobarbital. A preoperative dose of dexamethasone (10 mg/kg IP) was also administered. - Photoreceptor Preparation
- The retina from the anesthetized 8-day-old rat was removed, flattened with radial cuts and placed with the receptor side down on a gelatin slab secured to the vibratome chuck. Molten gelatin (4-5% solution) was deposited adjacent the retina at the retina/gelatin interface and then cooled to 4.degree. C. with ice-cold Ringer's solution. The retina was sectioned at 20 to 50 μm until the photoreceptor layer was reached. When the photoreceptor layer was reached, the stage was advanced and a thick (200 to 300 μm) section was taken, undercutting the photoreceptor layer secured to the gelatin base.
- Dil Labeling
- The isolated outer nuclear layer was cultured overnight with 40 μg/ml of dil (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate in Earle's MEM containing 10% fetal calf serum, incubated under 95%/5% oxygen/carbon dioxide mixture at room temperature. Labeling techniques and fluorescent microscopy were otherwise as outlined by Honig et al., J. Cell. Biol. 103:17, 1986. Dil was removed from sections that were to be counterstained with FITC-labeled RET-P1 opsin antibody by prior washing in acetone.
- Surgical Procedure
- A transverse incision was made in the cornea sufficient to allow insertion of a
surgical instrument 10 that is 2.5 mm wide with side rails 0.5 mm high orsurgical instrument 30. The instrument was advanced under the iris (dilated with topical atropine) to the ora serrata, detaching the retina. The carrier was then advanced under the retina into the subretinal space to the posterior pole of the eye. The instrument allowed a graft comprising a piece of the photoreceptor layer attached to the gelatin substrate (up to 2.5×4 mm) to be guided into the retinal space by fine forceps. The instrument was then removed while the gelatin was held in position by the forceps. Following removal of the forceps, the edges of the corneal incision were abutted to allow rapid, sutureless healing. The eye was patched during recovery and a prophylactic dose of penicillin was administered. Upon removal of the patch, a veterinary ophthalmic antibiotic ointment was applied. - Transplant recipients were maintained on a 12 hr/12 hr light/dark cycle with an average light intensity of 50 lux. Following appropriate survival times, the animal was overdosed with pentobarbital and perfused transcardially with phosphate buffered 3% paraformaldehyde-2% gluteraldehyde solution. Cryostat sections of both the light-blinded eye (control) and the eye receiving the photoreceptor transplant were then cut (20 μm).
- Immunohistochemistry
- Antibody labeling for opsin was performed on retinas fixed with 3% paraformaldehyde and cryosectioned at 20 μm. Immunohistocheinical methods were otherwise as described in Hicks, et al., J. Histochem Cytochem 35:1317 (1987). Elimination of the primary antibody eliminated specific labeling for opsin.
- Cryostat Sections
- Cryostat sections made at 4 weeks post-transplantation are shown in
FIGS. 22-24 .FIG. 22 is a low-power photomicrograph showing the location of the photoreceptor transplant (between arrowheads) at the posterior pole of the host eye Bar=0.5 mm.FIG. 23 is a higher-power photomicrograph showing the interface between the transplant and the adjacent retina devoid of outer nuclear layer. Arrows indicate the extent of the transplant (T). Arrowheads indicate three possible residual photoreceptors that survived constant illumination. Note their fusiform shape contrasts with the rounder, more normal shape of the transplanted photoreceptors. H & E stain. Bar=100 μm.FIG. 24 is a FITC fluorescent micrograph of antibody Ret P-1 specific for opsin in a section adjacent to that shown inFIG. 23 . Arrows indicate the extent of the transplant. Transplanted cells are labeled for opsin indicating they are photoreceptors. Some nonspecific fluorescence is evident adjacent to the transplant. Bar=100 μm. - Cryostat sections made at 3 weeks post-transplantation are shown in FIGS. 25A-C.
FIG. 25A is a H & E-stained photomicrograph of a transplant and host retina. Note the cell-sparse layer that resembles the outer plexiform layer interposed between the host retina and the transplant.FIG. 25B is a dil fluorescent photomicrograph of adjacent section. Transplanted photoreceptors show dil fluorescence, identifying them as donor tissue.FIG. 25C is a FITC fluorescent micrograph of antibody RET-P1 in a section adjacent to that shown inFIG. 25A . Transplanted cells are labeled for opsin, indicating that they are photoreceptors. Bar=50 μm. - Results
- By using the transcorneal approach, it was found that the positioning of the photoreceptor layer between the host's retina and the adjacent epithelial and choroidal tissue layers of the eye could be accomplished while minimizing the vascular damage and subsequent bleeding into the eye. In addition, it was found that this approach does not appear to disrupt the integrity of the retina, which reattaches to the back of the eye with the transplanted photoreceptors interposed between the retina and the RPE. As shown in
FIGS. 21-24 , retinal reattachment appears to be facilitated in the immediate area of the transplant. (The “T” indicates transplanted sheets of photoreceptor cells). Using this insertion method, it was possible to position the photoreceptors at the posterior pole of the retina (FIG. 22 ). - To determine the viability of the transplanted photoreceptors, cryostat sections (20 μm) were made from both the blinded eye (control) and the eye receiving the photoreceptor transplant at 2, 4, or 6 weeks after transplantation. It was found that the photoreceptors survived transplantation at all times tested (36 out of 54 transplants). In most instances, the surviving transplant approximated its size at the time of transplantation. More importantly, there was no apparent reduction in transplant size with longer survival times, suggesting that the transplants were stable.
- As a control, the contralateral eyes that did not receive a photoreceptor transplant were examined. In these eyes, the retinas possessed very few residual photoreceptors located adjacent to the outer plexiform layer and the RPE. However, these residual cells were abnormal in their appearance, having flattened, pyknotic cell bodies instead of the rounded cell bodies of normal photoreceptors. Furthermore, the residual photoreceptors did not form an outer nuclear layer composed of columnarly stacked cell bodies, but instead were found in isolation, or at most appear as a single or double layer of cells (see
FIG. 23 ) located mainly in the peripheral retina. - The transplanted cells were easily distinguished from the residual photoreceptors by a number of parameters. First, they were found in discrete patches and have the characteristic columnar stacking arrangement of up to about 12 cell bodies that is characteristic of photoreceptor cells in the outer nuclear layer of the normal retina. They did not have the flattened appearance of the residual native photoreceptors, but instead have the round, nonpyknotic cell body typical of normal transplanted cells. Furthermore, the transplanted photoreceptors can form rosette configurations, a characteristic of transplanted and cultured retina while residual photoreceptors were not found in these configurations.
- To eliminate the possibility that the surgical procedure in some manner induced the regeneration of native photoreceptors, sham operations were performed. All procedures were performed as with the photoreceptor transplants except that no photoreceptors were attached to the inserted gelatin slab. While the retina reattached to the back of the eye, in no instance were patches of photoreceptors found.
- To positively identify the photoreceptor patches in experimental animals as transplanted tissue, the donor outer nuclear layer was labeled with the fluorescent marker dil prior to the transplantation. As shown in
FIG. 25B , the photoreceptor patches were fluorescently labeled while the host retina did not show dil fluorescence. - To confirm that the transplants consisted of photoreceptors, a monoclonal antibody specific for opsin, RET-P1 was used. As opsin is found only in photoreceptors, any cell showing labeling for opsin was, therefore, identified as a photoreceptor. As can be seen in
FIGS. 24 and 25 C, the transplanted cells stain intensely for opsin whereas other retinal cells are unstained. Positive staining for opsin not only identifies these cells as photoreceptors but indicates that these cells are still capable of producing the protein moiety of visual pigment. Retina adjacent to the region of the transplant shows only a few isolated photoreceptor cell bodies (FIG. 23 ) that do not stain for opsin (FIG. 24 ) suggesting that they are cones. Their lack of opsin staining, as well as their location and appearance in H & E-stained material, confirms that these cells are the host's residual photoreceptors (FIG. 23 ). - Harvesting the photoreceptor layer from the neonatal retina does not appear to disrupt tissue organization. Once transplanted, the photoreceptor layer maintained its characteristic columnar arrangement of cell bodies for all survival times examined, thus forming a new outer nuclear layer within the host's retina. In some cases, strict polarity was lost and the rosettes were formed. By light microscopy, the new layer appeared to be attached to the host's outerplexiform layer (
FIGS. 22 and 25 A). This layer normally is the site of synaptic contact between the photoreceptors and the retina. - The procedures of Example 1 were repeated except as noted. Substituted for the Sprague-Dawley rats were the rd mouse and the RCS rat which are afflicted with inherited retinal degeneration. In the rd mouse it is thought that the deficit resides in the photoreceptor whereas in the RCS it is thought that the deficit resides in the pigment epithelium. In these animals, almost all photoreceptors are eliminated while the remaining retina is preserved; either the rd mouse or the RCS rat were blinded by constant illumination as set forth in Example 1. The rd mouse and the RCS respectively received transplants of immature (7-8 day old mouse or rat) and mature rat photoreceptors.
- rd Mouse
- The transplantation technique was adapted to the smaller size of the mouse eye. This modification allowed sheets of intact outernuclear layer to be transplanted to the subretinal space of the mouse eye. Neonatal (8 days old) photoreceptors were transplanted from rd control mice to the subretinal space of adult rd mice. Survival times were for 2 weeks to 3 months. At all survival times, it was found that the transplanted photoreceptors survived, becoming physically attached to the outer portion of the host retina and stained positive for opsin. In addition, the host retina became reattached to the pigment epithelium.
- In the rd mouse almost all photoreceptors are eliminated by day 21. It was found that photoreceptors from a non-dystrophic congenic control mouse can be transplanted to their appropriate site within the adult rd mouse eye that lacks photoreceptors. These transplanted photoreceptors were found to survive for as long as tested (3 months). This length of time is significant since photoreceptors of the rd mouse show signs of degeneration after about 2 weeks and are almost completely eliminated after 3 weeks. The survival of transplanted photoreceptors from congenic normal donors to the adult rd mouse within the rd mouse supports findings that indicate that the deficit within the rd mouse which causes the degeneration of photoreceptors is endogenous to the rd photoreceptors themselves.
- RCS Rat
- Photoreceptors from 7 to 8 day old RCS controls (normal) were transplanted to the subretinal space in the eye of adult (3 month old) RCS rats. A two month survival period was allowed because in this time period almost all host photoreceptors degenerate in the RCS rat. It was found that the grafted. photoreceptors survive transplantation to the subretinal space of the RCS rat and show histotypic as well as immunological characteristics of normal photoreceptors. In addition, it was found that transplanted photoreceptors survive within their homotopic location in the RCS rat whereas the RCS's own photoreceptors do not.
- Results
- While it has been found that the transplanted photoreceptors survive, produce opsin, and apparently integrate with the recipient retina, they do not appear completely normal in that the number of outer segments is reduced. However, photoreceptors lacking outer segments are still capable of phototransduction as indicated in Pu et al., J. Neorosci., 4:1559-1576, 1984. The relative scarcity of outer segments has also been noted in retina transplanted to the tecum. These retina have been shown to be functional as indicated in Simon et al., Soc. Neorosci. Abstr., 10:668, (1984).
- Conventional reasoning attributes the observed deficiency in outer segments to be the possible consequence of the lack of appropriate apposition of the RPE to the photoreceptors as indicated in LaVail et al., (1971), noted above. However, it has been found that RPE is present and in apparently normal apposition to the photoreceptors, thus, the scarcity of outer segments here would not appear to be related to inadequate contact between photoreceptor and RPE. The failure of outer segment growth in the presence of photoreceptor apposition to the RPE has also been seen following retinal reattachment as reported by Anderson et al., Invest Opthalmol. Vis, Sci. 24:906-926, 1983.
- The procedures of Example 1 were repeated except as noted.
- Donor photoreceptors were originally harvested at the earliest ontogenetic time in which the photoreceptors could be isolated from other portions of the retina (7-8 days old) since it is generally believed that more embryonic and undifferentiated neural tissue survives transplantation far better than more mature and differentiated tissue. To determine the effect of developmental age on photoreceptor survival and ability to integrate with the host retina, photoreceptors were subsequently transplanted from 8, 9, 12, 15 and 30 day old rats into light damaged adults. These show progressive development and maturation of the photoreceptors including mature outer segments (at 15 and 30 days).
- Using the same criteria as in Example 1, it was found that for all ages tested the transplants survived for as long as examined (2 months) and integrated with the host retina.
FIG. 26 , panel A, is a photograph of a transplant of mature photoreceptors (30 day old donor) to adult light damaged host. (T, Transplant). 120X. These observations suggest that photoreceptors have characteristics that differ from other neural tissue that permits them to be transplanted when they are essentially mature while other neural tissue must be at a very immature stage for successful transplantation to occur. - The procedures of Example 1 were repeated except as noted. Photoreceptors were taken from the retina of donated human eyes (obtained from the Missouri Lions and St. Louis Eye Banks) following corneal removal. A portion of the retinas were tested for viability by dye exclusion with trypan blue and didansyl cystine staining. The photoreceptors excluded dye and appeared to be in good condition. Hosts were adult albino rats (immune-suppressed with cyclosporin A or immune-competent) exposed to constant illumination.
- With immune-suppression successful transplants were seen at all survival times so far examined (one and two weeks; five of nine cases), showing apparent physical integration with the host retina and maintaining morphological features of the outer nuclear layer as illustrated in
FIG. 26B which shows a transplant of human photoreceptors from adult donor to adult light damaged rat host. (T, transplant). 120X. - The transplants stained positive for antiopsin antibody RET-P1, identifying the transplanted cells as photoreceptors and further indicating that they are still capable of producing visual pigment. In contrast, transplants to immune-competent hosts showed signs of rejection within one week of transplantation. Sham operated animals showed no repopulation of the host retina with photoreceptors.
- The procedures of Example 1 were repeated except as noted.
- The 2DG functional mapping technique developed by Sokoloff et al., J. Neurochem. 28:897-916 (1977) allows the measurement of the relative levels of neural activity for a given stimulus condition. For this reason, the 2DG technique appeared to be an appropriate method of assessing the functional characteristics of the transplant and its ability to activate the light damaged retina.
- Accordingly, patterns of 2DG uptake in the normal retina were compared to that seen in the light-damaged retina, with and without a photoreceptor transplant. These comparisons were made under two different visual stimulus conditions: 1) darkness and 2) strobe flicker at 10 z.
FIG. 27 illustrates the results of these comparisons. H&E stained retina with corresponding 2-deoxyglucose autoradiographs. A and B normal retina. Sections cut slightly tangentially to expand retinal layers. C. Dystrophic (light-damaged) retina plus photoreceptor transplant (T) left of arrow. Black and white lines at left on 2DG autoradiograph bracket lower 2DG uptake in inner plexiform and ganglion cell layers. D. Dystrophic retina plus photoreceptor transplant left of arrow. ONL; outer nuclear layer, T; transplant, DYST; dystrophic, Bar=0.5 mm. - As shown in panel 27A, in darkness 2DG was preferentially taken up in the outer portion of normal retina (photoreceptors and possibly the inner nuclear layer). As shown in panel 27B, with strobe flicker stimulation 2DG uptake extends through the thickness of the normal retina. These patterns of 2DG uptake are in good agreement with the known physiological characteristics of the retina.
- The outer retina might be expected to show high 2DG uptake in the dark since photoreceptors, horizontal and some bipolar cells are maximally depolarized in this situation. As strobe flicker is a strong stimulus for the retina including the amacrine and retinal ganglion cells, 2DG uptake across the entire retina is also to be expected. It therefore appears that the 2DG uptake pattern in normal retina reflects relative degrees of neural activity or neural depolarization, and therefore is a useful indicator of neural activity in the retina as it is in other areas of the nervous system.
- In the light-damaged retina which received a photoreceptor transplant, the pattern of 2DG uptake was also dependent on the stimulus conditions. In the dark, preferential uptake of 2DG was limited to the photoreceptor transplant and the adjacent host inner nuclear layer while relatively lower uptake was present in the host's inner plexiform and ganglion cell layers. However, in the strobe flicker condition, high 2DG uptake is present in the transplant and, in addition, extended through the thickness of the host's retina—but only in the area of the photoreceptor graft (
FIG. 27D ). Adjacent host retina which did not receive the photoreceptor transplant shows relatively low 2DG uptake. - In darkness, both the normal retina and the light-damaged retina receiving the photoreceptor transplant show relatively high uptake of 2DG in the photoreceptor and inner nuclear layers. The similarity in the relative uptake patterns between these cases suggests that the transplanted photoreceptors may have similar functional characteristics as normal photoreceptors (i.e., they depolarize in the dark and are capable of inducing a sustained depolarization of some cells in the host's inner nuclear layer).
- In strobe flicker, the light-damaged retina receiving the photoreceptor transplant showed high 2DG uptake through the entire thickness of the retina much like that seen in the normal retina under the same stimulus condition. Adjacent light-damaged retina that did not receive a photoreceptor transplant showed relatively low 2DG uptake. These comparisons show that the pattern of 2DG uptake in the light-damaged retina approximates that seen in the normal retina only in areas of the host retina that received photoreceptor grafts. Adjacent areas of the host retina show relatively low levels of 2DG uptake in both stimulus conditions. The similarity in the 2DG uptake patterns between the light-damaged retina following photoreceptor grafting and the normal retina in both stimulus conditions suggests that the photoreceptor transplant is capable of light-dependent activation of the light-damaged retina.
- The procedures of Example 1 were repeated except as noted.
- While activation of the host retina by the transplanted photoreceptors was seen with deoxyglucose mapping the nature of this activation was unclear. Specifically, does such activation represent a nonsynaptic modulation of neurotransmitter release by the transplanted photoreceptors or are the transplanted cells forming synapses with elements of the host retina?
- To address this issue, the ultrastructure of the reconstructed retina was investigated. Following appropriate survival times, animals were euthanized by overdose and immediately enucleated. Control and experimental eyes for light microscopy were fixed overnight in Bouin's solution. Following dehydration and clearing, the tissue was embedded in paraffin. Sections were cut on a rotary microtome. Eyes destined for plastic embedment were fixed for 2 hours in buffered 2.5% glutaraldehyde. After ½ hour of aldehyde fixation, the anterior segment and lens were removed to facilitate penetration of the fixative. Following primary fixation, eyes for light microscopy were processed further for methacrylate embedding. Two to 5 μm sections were cut on a rotary microtome using glass “Ralph” knives. In eyes for ultrastructural analysis, the area receiving the transplant was localized using the Dil label and excess tissue was trimmed before osmium posifixation. Following dehydration and clearing, the tissue was embedded in Epon/Araldite (Mollenhauer, 1964). Blocks were surveyed by staining semithin sections with toluidine blue. When the transplant was located, thin sections were cut and stained with uranyl acetate and lead citrate for examination on the EM.
- A new outer plexiform-like layer was visible at the interface of the transplanted ONL and the host inner nuclear layer. Ribbon synapses were evident within this OPL. These synapses are characteristic of those formed by rod photoreceptors, with an electron dense ribbon surrounded by a cluster of vesicles. Ribbon synapses are found only rarely in control light-damaged retina. In addition to ribbon synapses, the transplanted photoreceptors also display inner segments, connecting cilia, and outer segment membranes. These results suggest that synaptic connections between transplanted photoreceptors and host cells were made indicating that the light-dependent activation may, at least in part, be synaptically mediated.
- The procedures of Example 1 were repeated except as noted.
- The functional capabilities of the transplanted photoreceptors and reconstructed retina was ascertained by recording visually evoked cortical potentials (“VEP”). To record the VEP, animals were implanted with stainless-steel screw electrodes embedded in the skull. The active electrodes were placed 2 mm anterior to lambda (bilaterally), and referred to a second electrode placed anterior to bregma. Both electrodes were placed 2 mm lateral to the midline and positioned on the dura. A third screw was placed above the nasal cavity to serve as a ground electrode.
- Responses of the VEP were elicited by strobe flash test stimuli generated by a GRASS PS-2 photostimulator directed toward one eye with the other eye covered by a patch. Responses were differentially amplified (GRASS P-15D preamp), displayed on a TECTRONIX #564 oscilliscope and then averaged by a MACINTOSH IIx computer using LABVIEW.
- It was found that the reconstructed retina can produce a light-evoked electrical response in the visual cortex whereas the unreconstructed fellow eye showed little or no response to the same light stimulus.
- The procedures of Example 1 were repeated except as noted.
- With indications that neural activity is generated in the central nervous system by the photoreceptor transplant and the reconstructed retina the question arises at to whether this neural activity can be processed appropriately by the central nervous system to produce an appropriate behavioral response to the sensory stimuli. Previous studies have shown that neural transplants to the brain can restore appropriate behavioral activity (Bjorklund et al., Neural Grafting in the Mammalian CNS. Elsevier, Amsterdam, 1985). Klassen and Lund Proc. Natl. Acad. Sci. USA 84: 6958-6960, 1987; and Exp. Neurol. 102: 102-108, 1988 have shown that neural transplants can restore the pupillary reflex mediated by intracranial transplantation of embryonic retinas thus showing that neural transplants consisting of sensory tissue are capable of mediating a behaviorally appropriate response to sensory stimulation.
- Rats with dystrophic retinas received a photoreceptor transplant as described in Example 1. At various post-surgical time intervals (E.G., 2, 4 and 8 weeks, etc.) animals were anesthesized and held in a stereotaxic device. An infrared video camera was focused on the eye through an operating microscope and the eye illuminated with infrared light. To test for pupillary reflex, a light beam controlled by a camera shutter within the operating microscope was used. This light was focused on the eye. The pupillary response to the light at graded intensities (intensity of the light was controlled by neutral density filters) was recorded by video camera connected to a frame grabber system. The pupillary reflex was then analysed using automated imageprocessing software (ULTIMATE, GTFS, Inc.)
- It was found that retinas reconstructed with photoreceptor transplants do in fact show a comparatively normal pupillary reflex to light (pupillary constriction) whereas the fellow dystrophic eye shows only a minimal reflex that is aberrant in form (pupillary dilation). The results are shown in
FIG. 28 a, 28 b, 28 c and 28 d. Panels a and b are of the reconstructed retina. Panel a shows the iris at light onset whereas panel b shows the same eye at 5 seconds after light onset. Comparison of panel a to panel b shows a normal pupillary constriction mediated by light. Panels c and d show the fellow blinded eye that received sham surgery with panel c showing the iris at light onset and panel d showing the iris 5 seconds later. Comparison of panels c and d show an increase in pupil size with light. This response is aberrant in form and is characteristic of individuals suffering from severe retinal dystrophy of a photoreceptor type. - These results show that neural transplantation can reconstruct the host's own sensory end organ—in this case the eye—to restore an appropriate behavioral response (i.e., the pupillary reflex) to sensory stimuli. These results have profound significance for the feasibility of the restoration of vision by photoreceptor transplantation.
- The procedures of Example 1 were repeated except as noted.
- Photoreceptors were taken from mature macaque retina (animals sacrificed for other research) or the retina of donated human eyes (obtained from the St. Louis Eye Bank) using vibratome sectioning of the flat-mounted retina to isolate the intact outer nuclear layer. Hosts were mature macaque monkeys treated with iodoacetic acid (30 mg/kg given on 3 successive days) which selectively eliminates host photoreceptors in non-macular areas of the retina while leaving the remaining retina intact. This treatment did not compromise central vision and therefore maintained sight required for behavioral and physiologically important functions (e.g., locating of food and water, visually guided locomoter activities, grooming, maintenance of circadian rhythms).
- The isolated outer nuclear layer was transplanted following a pars plana vitrectomy (a standard surgical technique) using a trans-scleral approach to the subretinal space. The photoreceptors were inserted under a focal retinal detachment induced by the formation of a subretinal bleb. The bleb was created by the infusion of ophthalmic balanced salt solution. The reconstructed retina was reattached to the back of the eye by pneumatic tamponade with the transplanted photoreceptors interposed between the retina and the underlying pigment epithelium. Daily injections of cyclosporin A and dexamethasone were made to suppress any possible transplant rejection.
- It was found human photoreceptors survive transplantation to the non-human primate eye for as long as tested (2 weeks). These results indicate that mature human photoreceptors can be transplanted to the non-human primate eye. Since the non-human primate eye is almost identical to the human eye it is expected that human photoreceptors can be successfully transplanted to the human eye.
- From the foregoing description those skilled in the art will appreciated that all aspects of the present invention are realized. The present invention provides an improved surgical instrument that is adapted to provide cell organization during transplantation of the photoreceptors. With the surgical instrument of this invention cell organization is maintained during photoreceptor, RPE, and choroidal transplantation while minimizing trauma to the transplanted tissues, the host eye and retina. It is believed that retina reattachment and subsequent substantially normal function of the reconstructed retina, in view of the transplant, is thereby facilitated. The present invention provides an improved surgical instrument that is constructed to allow relatively large expanses of the RPE, choroidea, and photoreceptor cell matrix or column to be transplanted to a sub-retinal space. Maintaining normal layer configuration of the photoreceptors, RPE, and choroidea allows these tissues to be transplanted to the appropriate position within the eye. The subsequent integration of the transplanted photoreceptors, RPE, and choroidea with the blinded retina facilitates reconstruction of the blinded retina. The present invention provides an improved surgical instrument that allows appropriate retinotopic positioning. The present invention provides an improved surgical instrument that protects photoreceptors from damage as the surgical device is positioned in the eye. The present invention provides a method of photoreceptor or retinal pigment epithelium isolation and transplantation that, maintains to the extent possible the normal organization of the outer nuclear layer and these other tissues. The present invention provides a method of cell and tissue isolation by which cells can be isolated without disruption of their intercellular organization. With the method of this invention retinal cells, such as retinal photoreceptors can be isolated without the disruption of the intercellular organization of the outer nuclear layer or other layer of the retina, RPE, and choroidea.
- A number of features of the transplanted cells are that they are and remain alive; they produce opsin, important for phototransduction; they are functional (i.e., activated by light); and the transplanted photoreceptors activate a previously blinded retina in a light dependent fashion.
- Attachment of retinal tissue to the gelatin substrate allows extended periods of in vitro culture of retinal tissues by: maintaining organization of tissue in culture; and allowing for a better viability of cultured tissue.
- While a number of embodiments have been shown and described, many variations are possible. Photoreceptors can be transplanted to retina in which the host's or recipient's photoreceptors are lost by environmental (constant light) or inherited defects. (See: S. E. Hughes and M. S. Silverman (1988) in “Transplantation of retinal photoreceptors to dystrophic retina”, Soc. Neurosci. Abstr., 18: 1278.) Furthermore transplanted photoreceptor cells maintain basic characteristics of normal photoreceptor cells by producing opsin and maintaining an intercellular organization and apposition to the host retina that is similar to that seen in the normal outer nuclear layer. The surgical instruments may be larger for use in humans. Other approaches to the subretinal space may be used, e.g., trans-scleral, choroidal. Other substrates besides gelatin can be used, e.g. agar, agarose, in fact improved substrates could include factors that can be integrated into gelatin, for example, neurotrophic factors). It is believed that attachment to gelatin or equivalent substrates will allow prolonged in vitro culture, or cryogenic freezing, and similar storage, while allowing for the maintenance of tissue organization and viability. Finally, it is believed that other methods of attaching retina to substrate can be used, such as lectins, or photo-activated cross-linking agents.
- It has been shown that this invention provides a method to isolate the intact photoreceptor layer. This is significant because it will be necessary to maintain tight matrix organization if coherent vision is to be restored to the retina comprised by the loss of photoreceptors. A surgical approach has been disclosed which minimizes trauma to the eye and allows controlled positioning of sheets of transplanted photoreceptors to their homotopic location within the eye. In addition these methods for transplantation and isolation of photoreceptors could be utilized to prepare and transplant other retinal layers so that selected populations of retinal cells can be used in other neurobiological investigations and clinical procedures. It is believed that these other retinal layers, once they are flattened, appropriately sectioned, and appropriately affixed to a stabilizing substrate or base, could be prepared for transplantation, storage (e.g., in vitro, cryogenic), or culturing similar to the methods described herein for photoreceptor layers.
- The necessity for prompt re-vascularization typically limits the ability to transplant most neural tissue, but not photoreceptors. The photoreceptor layer of a retina and the (“RPE”) is non-vascularized. Non-vascularized tissue shows the least amount of tissue rejection. Consequently, it is believed that genetically dissimilar photoreceptor cells may be transplanted in accordance with the present invention. Matching of host and donor histocompatibility antigens will probably be necessary for transplantation of the retinal pigment epithelium and choroidea.
- Photoreceptors can be transplanted when developing or when mature. Not only can mature rat photoreceptors be transplanted, but mature photoreceptors from human donors can be transplanted as well. This is significantly different from neurons which must be immature in order to be transplanted. At present the reason for this difference is not known but has obvious importance for retinal and neural transplantation research in general.
- Finally, transplanted photoreceptors activate the host's or recipient's dystrophic retina in a light dependent manner that closely resembles the activation pattern seen in normal retina.
- In view of the above, it will be seen that the several objects of the invention are achieved and other advantages attained.
- As various changes could be made in the above surgical instruments, compositions of matter and methods. Without, departing from the scope of the invention, it is intended that all matter contained in the above description or shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.
Claims (20)
1. A retinal cell graft and instrument for implantation combination, wherein said instrument can be used to implant said retinal cell graft into a host eye, wherein,
said graft comprises a confluent population of cells from a donor eye, wherein said population is isolated from the retina of the donor eye, said population of cells comprising at least one of the group consisting of photoreceptor cells, and retinal pigment epithelial cells, said confluent population of cells having the same cell to cell organization in the graft as in the donor eye.
2. The combination of claim 1 , wherein said graft comprises photoreceptor cells and retinal pigment epithelial cells.
3. The combination of claim 2 , wherein said confluent population of cells isolated from retina comprises a portion of the retina lacking at least one layer of cells found in the intact retina prior to isolation therefrom.
4. The combination of claim 1 , wherein said cells are from an adult donor.
5. The combination of claim 2 , wherein said cells are from an adult donor.
6. The combination of claim 1 , wherein said instrument comprises:
an elongate tube having a distal end and a proximal end, said tube having a lumen passing from said proximal end to said distal end, said distal end having a distal tip, wherein said lumen forms an opening in said tip, said instrument further comprising a plunger,
said plunger and tube being capable of relative sliding motion with respect to each other, wherein the outer diameter of said distal end of said elongate tube is sufficiently small to be inserted through the pars plana area of an eye and the length of said distal end of said elongate tube is sufficient to permit said opening in said tip to be inserted beneath the retina through an opening therein, wherein relative sliding motion of said plunger and said tube can express solid or semisolid material within said lumen from said lumen through said opening in said tip into the subretinal space of an eye into which said tip is inserted.
7. The combination of claim 6 , wherein said cells are from an adult donor.
8. The combination of claim 6 , wherein said tube may be retracted with respect to said plunger to express said graft from said tip.
9. An instrument for subretinal implantation of a solid or semisolid therapeutic implant including a graft as recited in claim 1 , wherein the therapeutic implant can be a retinal cell graft comprising a confluent population of cells from a donor eye retina and the population of cells comprises at least one of the group consisting of photoreceptor cells, and retinal pigment epithelial cells, and the confluent population of cells has the same cell to cell organization in the graft as in the donor eye, said instrument comprising:
an elongate tube having a distal end and a proximal end, said tube having a lumen passing from said proximal end to said distal end, said distal end having a distal tip, wherein said lumen forms an opening in said tip, said instrument further comprising a plunger,
said plunger and tube being capable of relative sliding motion with respect to each other, wherein the outer diameter of said distal end of said elongate tube is sufficiently small to be inserted through the pars plana area of an eye and the length of said distal end of said elongate tube is sufficient to permit said opening in said tip to be inserted beneath the retina through an opening therein, wherein relative sliding motion of said plunger and said tube can express solid or semisolid material within said lumen from said lumen through said opening in said tip into the subretinal space of an eye into which said tip is inserted.
10. The instrument of claim 9 , further comprising a retinal cell graft that can be implanted in the subretinal space of a host eye, said retinal cell graft comprising a confluent population of cells from a donor eye, wherein said population is isolated from a retina and said population comprises at least one of the group consisting of photoreceptor cells, and retinal pigment epithelial cells.
11. The instrument of claim 10 , wherein said graft comprises a layer of human photoreceptor cells and a layer of retinal pigment epithelial cells.
12. The instrument of claim 10 , wherein said confluent population of cells comprises a portion of a human retina having at least one layer of cells found in an intact retina missing therefrom.
13. The instrument of claim 10 , wherein said cells are from an adult donor.
14. The instrument of claim 11 , wherein said cells are from an adult donor.
15. The instrument of claim 9 , wherein retraction of said tube with respect to said plunger will express an implant within said tube from said tip.
16. The instrument of claim 10 , wherein retraction of said tube with respect to said plunger will express an implant within said tube from said tip.
17. The instrument of claim 11 , wherein retraction of said tube with respect to said plunger will express an implant within said tube from said tip.
18. The instrument of claim 12 , wherein retraction of said tube with respect to said plunger will express an implant within said tube from said tip.
19. The instrument of claim 13 , wherein retraction of said tube with respect to said plunger will express an implant within said tube from said tip.
20. The instrument of claim 14 , wherein retraction of said tube with respect to said plunger will express an implant within said tube from said tip.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/171,876 US20060039993A1 (en) | 1989-08-14 | 2005-06-29 | Retinal cell grafts and instrument for implanting |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39437789A | 1989-08-14 | 1989-08-14 | |
US56699690A | 1990-08-13 | 1990-08-13 | |
US08/322,735 US5962027A (en) | 1989-08-14 | 1994-10-13 | Retinal cell transplant |
US09/411,122 US6579256B2 (en) | 1989-08-14 | 1999-10-04 | Instrument for subretinal implantation |
US10/323,958 US6955809B2 (en) | 1989-08-14 | 2002-12-17 | Retinal cell grafts |
US11/171,876 US20060039993A1 (en) | 1989-08-14 | 2005-06-29 | Retinal cell grafts and instrument for implanting |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/323,958 Division US6955809B2 (en) | 1989-08-14 | 2002-12-17 | Retinal cell grafts |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060039993A1 true US20060039993A1 (en) | 2006-02-23 |
Family
ID=27014715
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/322,735 Expired - Fee Related US5962027A (en) | 1989-08-14 | 1994-10-13 | Retinal cell transplant |
US09/411,122 Expired - Fee Related US6579256B2 (en) | 1989-08-14 | 1999-10-04 | Instrument for subretinal implantation |
US10/323,958 Expired - Fee Related US6955809B2 (en) | 1989-08-14 | 2002-12-17 | Retinal cell grafts |
US11/171,876 Abandoned US20060039993A1 (en) | 1989-08-14 | 2005-06-29 | Retinal cell grafts and instrument for implanting |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/322,735 Expired - Fee Related US5962027A (en) | 1989-08-14 | 1994-10-13 | Retinal cell transplant |
US09/411,122 Expired - Fee Related US6579256B2 (en) | 1989-08-14 | 1999-10-04 | Instrument for subretinal implantation |
US10/323,958 Expired - Fee Related US6955809B2 (en) | 1989-08-14 | 2002-12-17 | Retinal cell grafts |
Country Status (2)
Country | Link |
---|---|
US (4) | US5962027A (en) |
SG (1) | SG49267A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070179512A1 (en) * | 2006-01-31 | 2007-08-02 | Olsen Timothy W | Surgical support structure |
US20090043321A1 (en) * | 2004-04-29 | 2009-02-12 | Iscience Interventional Corporation | Apparatus And Method For Surgical Enhancement Of Aqueous Humor Drainage |
US20100173866A1 (en) * | 2004-04-29 | 2010-07-08 | Iscience Interventional Corporation | Apparatus and method for ocular treatment |
US20100191103A1 (en) * | 2002-09-17 | 2010-07-29 | Iscience Interventional Corporation | Apparatus and method for surgical bypass of aqueous humor |
US20100191177A1 (en) * | 2009-01-23 | 2010-07-29 | Iscience Interventional Corporation | Device for aspirating fluids |
US20100241060A1 (en) * | 2009-03-18 | 2010-09-23 | Roizman Keith | Surgical devices and methods |
US8425473B2 (en) | 2009-01-23 | 2013-04-23 | Iscience Interventional Corporation | Subretinal access device |
JP2013230391A (en) * | 2007-03-28 | 2013-11-14 | Revision Optics Inc | Insertion system for corneal implants |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6514238B1 (en) * | 1989-08-14 | 2003-02-04 | Photogenesis, Inc. | Method for preparation and transplantation of volute grafts and surgical instrument therefor |
SG49267A1 (en) | 1989-08-14 | 1998-05-18 | Photogenesis Inc | Surgical instrument and cell isolation and transplantation |
US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
JP3703721B2 (en) | 1999-04-26 | 2005-10-05 | ジーエムピー ヴィジョン ソルーションズ インコーポレイテッド | Shunt device for treating glaucoma |
US6389317B1 (en) * | 2000-03-31 | 2002-05-14 | Optobionics Corporation | Multi-phasic microphotodetector retinal implant with variable voltage and current capability |
US20040039401A1 (en) * | 2000-03-31 | 2004-02-26 | Chow Alan Y. | Implant instrument |
US7135009B2 (en) | 2001-04-07 | 2006-11-14 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US6638239B1 (en) * | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
US7831305B2 (en) | 2001-10-15 | 2010-11-09 | Advanced Neuromodulation Systems, Inc. | Neural stimulation system and method responsive to collateral neural activity |
CA2429998C (en) | 2000-11-29 | 2012-01-17 | Oculex Pharmaceuticals, Inc. | Intraocular implants for preventing transplant rejection in the eye |
US6875165B2 (en) | 2001-02-22 | 2005-04-05 | Retinalabs, Inc. | Method of radiation delivery to the eye |
US7037943B2 (en) | 2001-04-10 | 2006-05-02 | Optobionics Corporation | Retinal treatment method |
US6939378B2 (en) * | 2001-06-01 | 2005-09-06 | The Board Of Trustees Of The Leland Stanford Junior University | Microfabricated tissue as a substrate for pigment epithelium transplantation |
US7485113B2 (en) * | 2001-06-22 | 2009-02-03 | Johns Hopkins University | Method for drug delivery through the vitreous humor |
JP4115935B2 (en) * | 2001-06-29 | 2008-07-09 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | Artificial synaptic chip interface for electronic artificial retina |
US7147865B2 (en) * | 2001-06-29 | 2006-12-12 | The Board Of Trustees Of The Leland Stanford University | Artificial synapse chip |
WO2003018040A1 (en) * | 2001-08-24 | 2003-03-06 | The Schepens Eye Research Institute, Inc. | Composite graft for treatment of retinal diseases |
WO2003061519A2 (en) | 2002-01-18 | 2003-07-31 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US7189245B2 (en) * | 2002-02-14 | 2007-03-13 | Photogenesis, Inc. | Subretinal implantation device and surgical cannulas for use therewith |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US8231637B2 (en) * | 2002-07-26 | 2012-07-31 | Second Sight Medical Products, Inc. | Surgical tool for electrode implantation |
CA2498489C (en) * | 2002-09-29 | 2010-02-23 | Surmodics, Inc. | Method for subretinal administration of therapeutics including steroids;method for localizing pharmacodynamic action at the choroid and the retina; and related methods for treatment and/or prevention of retinal diseases |
US7141048B1 (en) * | 2002-10-17 | 2006-11-28 | Alcon, Inc. | Vitreoretinal instrument |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US20130178789A1 (en) * | 2003-01-29 | 2013-07-11 | Novartis Ag | Monitoring Thermal Conditions To Vary Operation of an Ultrasonic Needle Tip of a Surgical Instrument |
US20040152990A1 (en) * | 2003-01-29 | 2004-08-05 | Mackool Richard J. | Monitoring thermal conditions to vary operation of an ultrasonic needle tip of a surgical instrument |
US7483750B2 (en) * | 2003-03-21 | 2009-01-27 | Second Sight Medical Products, Inc. | Transretinal implant and method of implantation |
US7321795B2 (en) * | 2003-03-24 | 2008-01-22 | Les Bogdanowicz | Compositions for electric stimulation of the eye |
US20040225250A1 (en) | 2003-05-05 | 2004-11-11 | Michael Yablonski | Internal shunt and method for treating glaucoma |
US20040243095A1 (en) | 2003-05-27 | 2004-12-02 | Shekhar Nimkar | Methods and apparatus for inserting multi-lumen spit-tip catheters into a blood vessel |
IL157981A (en) | 2003-09-17 | 2014-01-30 | Elcam Medical Agricultural Cooperative Ass Ltd | Auto-injector |
IL157984A (en) | 2003-09-17 | 2015-02-26 | Dali Medical Devices Ltd | Autoneedle |
US20050070919A1 (en) * | 2003-09-26 | 2005-03-31 | Lieberman Daniel M. | Device for guiding insertion of a medical device into the spinal epidural space and method therefor |
US7291125B2 (en) * | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
US7563222B2 (en) * | 2004-02-12 | 2009-07-21 | Neovista, Inc. | Methods and apparatus for intraocular brachytherapy |
EP2298412A1 (en) | 2004-02-12 | 2011-03-23 | Neovista, Inc. | Apparatus for intraocular brachytherapy |
IL160891A0 (en) | 2004-03-16 | 2004-08-31 | Auto-mix needle | |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US8992454B2 (en) | 2004-06-09 | 2015-03-31 | Bard Access Systems, Inc. | Splitable tip catheter with bioresorbable adhesive |
US20060110428A1 (en) * | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
US7803375B2 (en) | 2005-02-23 | 2010-09-28 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
EP1868661A1 (en) * | 2005-04-08 | 2007-12-26 | SurModics, Inc. | Sustained release implants for subretinal delivery |
WO2007019427A2 (en) * | 2005-08-08 | 2007-02-15 | Massachusetts Eye & Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
BRPI0618677A2 (en) | 2005-11-15 | 2011-09-06 | Neovista Inc | methods and apparatus for intraocular brachytherapy |
ES2762239T3 (en) | 2006-01-17 | 2020-05-22 | Alcon Inc | Glaucoma treatment device |
US8802128B2 (en) * | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US20080255578A1 (en) * | 2007-02-09 | 2008-10-16 | Fisher Surgical | Corneal endothelial tissue inserter |
US8956866B2 (en) | 2007-04-18 | 2015-02-17 | Hadasit Medical Research Services And Development Ltd. | Retinal pigment epithelial cells differentiated from embryonic stem cells with nicotinamide and activin A |
WO2008141309A1 (en) * | 2007-05-11 | 2008-11-20 | Ension, Inc. | Apparatus and method for endothelial keratoplasty donor tissue transport and delivery |
US8292841B2 (en) | 2007-10-26 | 2012-10-23 | C. R. Bard, Inc. | Solid-body catheter including lateral distal openings |
US8066660B2 (en) | 2007-10-26 | 2011-11-29 | C. R. Bard, Inc. | Split-tip catheter including lateral distal openings |
CN101918067B (en) | 2007-11-01 | 2013-04-10 | C·R·巴德股份有限公司 | Catheter assembly including triple lumen tips |
US9579485B2 (en) | 2007-11-01 | 2017-02-28 | C. R. Bard, Inc. | Catheter assembly including a multi-lumen configuration |
CN101969898B (en) | 2007-11-08 | 2013-09-18 | 阿利梅拉科学公司 | Ocular implantation device |
US20100152646A1 (en) * | 2008-02-29 | 2010-06-17 | Reshma Girijavallabhan | Intravitreal injection device and method |
BRPI0913380A2 (en) | 2008-06-04 | 2015-11-24 | Neovista Inc | portable radiation release system for advancing a radiation source wire |
EP3735947B1 (en) | 2009-01-28 | 2022-05-04 | Alcon Inc. | Ocular implant delivery system |
US8057483B2 (en) | 2009-02-14 | 2011-11-15 | Ocular Transplantation Llc | Subretinal implantation instrument |
CN102427776B (en) * | 2009-04-16 | 2016-02-24 | 学校法人庆应义塾 | Transplantation device |
WO2011066451A2 (en) | 2009-11-24 | 2011-06-03 | Olsen Timothy W | Tissue support structure |
EP2570139B1 (en) * | 2010-05-10 | 2019-08-07 | Tsutomu Yasukawa | Method for producing cell sheet |
US20130077048A1 (en) * | 2010-06-10 | 2013-03-28 | Ram Srikanth Mirlay | Integrated fiber optic ophthalmic intraocular surgical device with camera |
GB201011313D0 (en) * | 2010-07-05 | 2010-08-18 | Ucl Business Plc | Implantation devices, methods and implants |
US9777255B2 (en) * | 2010-12-14 | 2017-10-03 | Morehouse School Of Medicine | Methods and storage and retrieval of functional mature retinal cells |
WO2012149468A2 (en) * | 2011-04-29 | 2012-11-01 | University Of Southern California | Instruments and methods for the implantation of cell-seeded substrates |
CA3098762C (en) | 2012-03-26 | 2023-01-17 | Glaukos Corporation | System and method for delivering multiple ocular implants |
US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
AU2013306720B2 (en) * | 2012-08-24 | 2018-10-18 | Riken | Method for producing retinal pigment epithelial cell sheet |
ES2633185T3 (en) | 2012-09-17 | 2017-09-19 | Novartis Ag | Expandable eye implant devices |
WO2014078288A1 (en) | 2012-11-14 | 2014-05-22 | Transcend Medical, Inc. | Flow promoting ocular implant |
JP6426110B2 (en) | 2013-02-01 | 2018-11-21 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Methods for generating retinal pigment epithelial (RPE) cells derived from population pluripotent stem cells (IPSCs) |
US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
KR101871084B1 (en) | 2013-12-11 | 2018-06-25 | 화이자 리미티드 | Method for producing retinal pigment epithelial cells |
CA2954762A1 (en) * | 2014-07-11 | 2016-01-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Surgical tool and method for ocular tissue transplantation |
US10258768B2 (en) | 2014-07-14 | 2019-04-16 | C. R. Bard, Inc. | Apparatuses, systems, and methods for inserting catheters having enhanced stiffening and guiding features |
WO2016023116A1 (en) * | 2014-08-12 | 2016-02-18 | Patrick Gooi | Device, delivery system, and method for ocular therapy |
US20180011092A1 (en) | 2014-12-30 | 2018-01-11 | Cell Cure Neurosciences Ltd. | Assessing retinal pigment epithelial cell populations |
SG11201705379VA (en) | 2014-12-30 | 2017-08-30 | Cell Cure Neurosciences Ltd | Rpe cell populations and methods of generating same |
US11230696B2 (en) | 2015-07-29 | 2022-01-25 | Hadasit Medical Research Services And Development Ltd. | Large scale production of retinal pigment epithelial cells |
PL3331994T3 (en) | 2015-08-05 | 2023-01-30 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
AU2016303631B2 (en) | 2015-08-05 | 2022-07-28 | Cell Cure Neurosciences Ltd. | Preparation of photoreceptors for the treatment of retinal diseases |
EP3347457B1 (en) | 2015-09-08 | 2021-10-27 | FUJIFILM Cellular Dynamics, Inc. | Macs-based purification of stem cell-derived retinal pigment epithelium |
DK3347456T3 (en) | 2015-09-08 | 2024-02-19 | Us Health | PROCEDURE FOR REPRODUCIBLE DIFFERENTIATION OF CLINICAL-GRADE RETINAL PIGMENT EPITHELIAL CELLS |
JP6987769B2 (en) | 2015-10-26 | 2022-01-05 | セル キュア ニューロサイエンシズ リミテッド | Preparation method of retinal pigment epithelial cells |
JP6930975B2 (en) * | 2015-12-14 | 2021-09-01 | アルコン インコーポレイティド | Patches and related devices, systems, and methods for sealing retinal detachments |
EP3595687A1 (en) | 2017-03-16 | 2020-01-22 | Lineage Cell Therapeutics, Inc. | Methods for measuring therapeutic effects of retinal disease therapies |
EP3415117A1 (en) * | 2017-06-15 | 2018-12-19 | Laser Vista AG | Intraocular lens implant |
EP3731789A4 (en) | 2017-12-29 | 2021-09-08 | Cell Cure Neurosciences Ltd. | Retinal pigment epithelium cell compositions |
EP3829501A4 (en) * | 2018-08-03 | 2022-05-04 | The Johns Hopkins University | Retinal implantation device |
US20220016318A1 (en) | 2018-11-19 | 2022-01-20 | The United State Of America, As Represented By The Secretary, Deparment Of Health And Human Services | Biodegradable tissue replacement implant and its use |
US20200375844A1 (en) * | 2019-05-29 | 2020-12-03 | Alcon Inc. | Retina massage and smoothing device |
EP3754014A1 (en) | 2019-06-21 | 2020-12-23 | Centre d'Etude des Cellules Souches (CECS) | Automated method for preparing retinal pigment epithelium cells |
JP2024520423A (en) | 2021-05-28 | 2024-05-24 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Biodegradable tissue scaffolds with secondary matrices to accommodate weakly adherent cells - Patent Application 20070123333 |
US20240271089A1 (en) | 2021-05-28 | 2024-08-15 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Methods to generate macular, central and peripheral retinal pigment epithelial cells |
JP2024522608A (en) | 2021-06-09 | 2024-06-21 | リネージ セル セラピューティクス インコーポレイテッド | Methods and compositions for treating retinal diseases and conditions |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3934591A (en) * | 1974-03-20 | 1976-01-27 | Gleason Robert W | Dermatome |
US4014342A (en) * | 1975-04-11 | 1977-03-29 | Concept, Inc. | Vitreous cutter |
US4304866A (en) * | 1979-11-14 | 1981-12-08 | Massachusetts Institute Of Technology | Transplantable sheets of living keratinous tissue |
US4393872A (en) * | 1980-05-27 | 1983-07-19 | Eder Instrument Co., Inc. | Aspirating surgical forceps |
US4418691A (en) * | 1981-10-26 | 1983-12-06 | Massachusetts Institute Of Technology | Method of promoting the regeneration of tissue at a wound |
US4495288A (en) * | 1981-03-13 | 1985-01-22 | Damon Biotech, Inc. | Method of culturing anchorage dependent cells |
US4563779A (en) * | 1984-01-27 | 1986-01-14 | Kelman Charles D | Corneal implant and method of making the same |
US4655774A (en) * | 1986-01-03 | 1987-04-07 | Choyce D Peter | Intra-corneal implant for correction of aniridia |
US4662869A (en) * | 1984-11-19 | 1987-05-05 | Wright Kenneth W | Precision intraocular apparatus |
US4689399A (en) * | 1984-12-24 | 1987-08-25 | Collagen Corporation | Collagen membranes for medical use |
US4693686A (en) * | 1986-02-14 | 1987-09-15 | Sendax Victor I | Magnetic dental implant retention system |
US4702697A (en) * | 1986-02-14 | 1987-10-27 | Linkow Leonard I | Prefabricated partial subperiosteal implant |
US4727018A (en) * | 1984-05-18 | 1988-02-23 | Eichner Ronald D | Immunoregulation of transplantable tissue |
US4868116A (en) * | 1985-07-05 | 1989-09-19 | Whitehead Institute For Biomedical Research | Introduction and expression of foreign genetic material in epithelial cells |
US4900300A (en) * | 1987-07-06 | 1990-02-13 | Lee David A | Surgical instrument |
US4927676A (en) * | 1988-07-01 | 1990-05-22 | Becton, Dickinson And Company | Method for rapid adherence of endothelial cells onto a surface and surfaces prepared thereby |
US4940468A (en) * | 1988-01-13 | 1990-07-10 | Petillo Phillip J | Apparatus for microsurgery |
US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5000963A (en) * | 1983-06-14 | 1991-03-19 | Hefton John M | Method of treating the skin using human epidermal sheets |
US5292802A (en) * | 1988-11-21 | 1994-03-08 | Collagen Corporation | Collagen-polymer tubes for use in vascular surgery |
US5322691A (en) * | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
US5323788A (en) * | 1992-09-21 | 1994-06-28 | Keravision | Overlapping split ring device for corneal curvature adjustment |
US5324260A (en) * | 1992-04-27 | 1994-06-28 | Minnesota Mining And Manufacturing Company | Retrograde coronary sinus catheter |
US5326584A (en) * | 1989-04-24 | 1994-07-05 | Drexel University | Biocompatible, surface modified materials and method of making the same |
US5326346A (en) * | 1992-07-27 | 1994-07-05 | Board Of Regents, The University Of Texas System | Light-cured urethane dimethacrylate ocular prosthesis |
US5328481A (en) * | 1988-06-21 | 1994-07-12 | Alcon Laboratories, Inc. | Method for injecting viscous fluid into the eye to lift retinal membrane |
US5339723A (en) * | 1993-09-30 | 1994-08-23 | Ethicon, Inc. | Pressurized fluid actuation system for amplifying operator input force in a surgical instrument |
US5342370A (en) * | 1993-03-19 | 1994-08-30 | University Of Miami | Method and apparatus for implanting an artifical meshwork in glaucoma surgery |
US5374515A (en) * | 1992-11-13 | 1994-12-20 | Organogenesis, Inc. | In vitro cornea equivalent model |
US5533981A (en) * | 1994-10-06 | 1996-07-09 | Baxter International Inc. | Syringe infusion pump having a syringe plunger sensor |
US5582617A (en) * | 1993-07-21 | 1996-12-10 | Charles H. Klieman | Surgical instrument for endoscopic and general surgery |
US5720742A (en) * | 1994-10-11 | 1998-02-24 | Zacharias; Jaime | Controller and actuating system for surgical instrument |
US5817075A (en) * | 1989-08-14 | 1998-10-06 | Photogenesis, Inc. | Method for preparation and transplantation of planar implants and surgical instrument therefor |
US5868728A (en) * | 1995-02-28 | 1999-02-09 | Photogenesis, Inc. | Medical linear actuator for surgical delivery, manipulation, and extraction |
US5941250A (en) * | 1996-11-21 | 1999-08-24 | University Of Louisville Research Foundation Inc. | Retinal tissue implantation method |
US5962027A (en) * | 1989-08-14 | 1999-10-05 | Photogenesis, Inc. | Retinal cell transplant |
US5993474A (en) * | 1996-06-11 | 1999-11-30 | Asahi Kogaku Kogyo Kabushiki Kaisha | Treatment accessory for endoscope |
US6045791A (en) * | 1992-03-06 | 2000-04-04 | Photogenesis, Inc. | Retinal pigment epithelium transplantation |
US6156042A (en) * | 1997-11-17 | 2000-12-05 | Aramant; Robert B. | Retinal tissue implantation instrument |
US6159218A (en) * | 1999-05-19 | 2000-12-12 | Aramant; Robert B. | Retinal tissue implantation tool |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US623A (en) * | 1838-03-03 | Machine eob cutting and dressing stone | ||
US604A (en) * | 1838-02-15 | Improvement in plows | ||
GB1109155A (en) * | 1964-07-15 | 1968-04-10 | Negretti & Zambia Ltd | An improved self-balancing potentiometer |
US3620216A (en) * | 1969-06-25 | 1971-11-16 | Abbott Lab | Implant trocar |
US3744493A (en) * | 1972-01-10 | 1973-07-10 | Syntex Corp | Implanter having an improved cartridge ejector |
US4197846A (en) * | 1974-10-09 | 1980-04-15 | Louis Bucalo | Method for structure for situating in a living body agents for treating the body |
US4086914A (en) * | 1977-02-11 | 1978-05-02 | Edwin Bailey Moore | Implant injector |
US4588395A (en) * | 1978-03-10 | 1986-05-13 | Lemelson Jerome H | Catheter and method |
US4451253A (en) * | 1980-12-18 | 1984-05-29 | Harman Sherman M | Means and method for administering medicinals |
US4753636A (en) * | 1983-08-02 | 1988-06-28 | Endocon, Inc. | Subcutaneous implant kit |
US4774091A (en) * | 1983-10-14 | 1988-09-27 | Sumitomo Pharmaceuticals Company, Ltd. | Long-term sustained-release preparation |
US4642094A (en) * | 1984-05-29 | 1987-02-10 | North Jr Walter L | Non-surgical embryo transfer device |
JPS616451A (en) * | 1984-06-20 | 1986-01-13 | Mazda Motor Corp | Hydraulic controller for automatic transmission |
US4820267A (en) * | 1985-02-19 | 1989-04-11 | Endocon, Inc. | Cartridge injector for pellet medicaments |
US4769011A (en) * | 1985-03-28 | 1988-09-06 | Interpore International, Inc. | Syringe apparatus and method for the surgical implantation of granular substances |
CH667209A5 (en) * | 1985-07-02 | 1988-09-30 | Sulzer Ag | MEDICAL DEPOT PROBE. |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4801263A (en) * | 1986-05-27 | 1989-01-31 | Clark William C | Osseous implant syringe |
DE3789320T2 (en) * | 1986-07-30 | 1994-06-09 | Sumitomo Pharma | Administration instrument for the introduction of solid medication. |
US4846793A (en) * | 1987-03-18 | 1989-07-11 | Endocon, Inc. | Injector for implanting multiple pellet medicaments |
DE3855054T2 (en) * | 1987-05-26 | 1996-07-18 | Nissho Kk | Device for the administration of solid preparations |
DE3802158A1 (en) * | 1987-08-11 | 1989-02-23 | Hoechst Ag | DEVICE FOR APPLICATION OF IMPLANTS |
ES2028991T3 (en) * | 1987-08-18 | 1992-07-16 | Akzo N.V. | INJECTION DEVICE, IN PARTICULAR FOR A SINGLE USE ONLY, TO INJECT AN IMPLANT UNDER THE SKIN. |
US4969912A (en) * | 1988-02-18 | 1990-11-13 | Kelman Charles D | Human collagen processing and autoimplant use |
US5510329A (en) * | 1988-04-26 | 1996-04-23 | Ramot University For Applied Research And Industrial Development Ltd. | Preparations for the treatment of eyes |
CH675828A5 (en) * | 1988-05-03 | 1990-11-15 | Arcofil Sa | |
US4909250A (en) * | 1988-11-14 | 1990-03-20 | Smith Joseph R | Implant system for animal identification |
EP0486589B1 (en) * | 1989-08-14 | 1998-03-04 | PHOTOGENESIS Incorporated | Surgical instrument and cell isolation |
DE4004921A1 (en) * | 1990-02-16 | 1991-08-22 | Klaus Prof Dr Med Mees | Cosmetic surgical instrument with cannula - is used for introduction and positioning of flat implants in human tissue |
US5273530A (en) * | 1990-11-14 | 1993-12-28 | The University Of Rochester | Intraretinal delivery and withdrawal instruments |
DE4132855A1 (en) * | 1991-10-02 | 1993-04-08 | Wisap Gmbh | INSTRUMENT FOR APPLICATION OF AN ADHAESION PROPHYLAXE FOR ENDOSCOPIC INTERVENTIONS |
US5507807A (en) * | 1994-03-01 | 1996-04-16 | Shippert; Ronald D. | Apparatus for the release of a substance within a patient |
US6436068B1 (en) * | 2000-08-24 | 2002-08-20 | Gust H. Bardy | Instrument for implanting sensors and solid materials in a subcutaneous location and method thereof |
-
1990
- 1990-08-13 SG SG1996008529A patent/SG49267A1/en unknown
-
1994
- 1994-10-13 US US08/322,735 patent/US5962027A/en not_active Expired - Fee Related
-
1999
- 1999-10-04 US US09/411,122 patent/US6579256B2/en not_active Expired - Fee Related
-
2002
- 2002-12-17 US US10/323,958 patent/US6955809B2/en not_active Expired - Fee Related
-
2005
- 2005-06-29 US US11/171,876 patent/US20060039993A1/en not_active Abandoned
Patent Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3934591A (en) * | 1974-03-20 | 1976-01-27 | Gleason Robert W | Dermatome |
US4014342A (en) * | 1975-04-11 | 1977-03-29 | Concept, Inc. | Vitreous cutter |
US4304866A (en) * | 1979-11-14 | 1981-12-08 | Massachusetts Institute Of Technology | Transplantable sheets of living keratinous tissue |
US4393872A (en) * | 1980-05-27 | 1983-07-19 | Eder Instrument Co., Inc. | Aspirating surgical forceps |
US4495288A (en) * | 1981-03-13 | 1985-01-22 | Damon Biotech, Inc. | Method of culturing anchorage dependent cells |
US4418691A (en) * | 1981-10-26 | 1983-12-06 | Massachusetts Institute Of Technology | Method of promoting the regeneration of tissue at a wound |
US5000963A (en) * | 1983-06-14 | 1991-03-19 | Hefton John M | Method of treating the skin using human epidermal sheets |
US4563779A (en) * | 1984-01-27 | 1986-01-14 | Kelman Charles D | Corneal implant and method of making the same |
US4727018A (en) * | 1984-05-18 | 1988-02-23 | Eichner Ronald D | Immunoregulation of transplantable tissue |
US4662869A (en) * | 1984-11-19 | 1987-05-05 | Wright Kenneth W | Precision intraocular apparatus |
US4689399A (en) * | 1984-12-24 | 1987-08-25 | Collagen Corporation | Collagen membranes for medical use |
US4868116A (en) * | 1985-07-05 | 1989-09-19 | Whitehead Institute For Biomedical Research | Introduction and expression of foreign genetic material in epithelial cells |
US4655774A (en) * | 1986-01-03 | 1987-04-07 | Choyce D Peter | Intra-corneal implant for correction of aniridia |
US4693686A (en) * | 1986-02-14 | 1987-09-15 | Sendax Victor I | Magnetic dental implant retention system |
US4702697A (en) * | 1986-02-14 | 1987-10-27 | Linkow Leonard I | Prefabricated partial subperiosteal implant |
US5322691A (en) * | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US4900300A (en) * | 1987-07-06 | 1990-02-13 | Lee David A | Surgical instrument |
US4940468A (en) * | 1988-01-13 | 1990-07-10 | Petillo Phillip J | Apparatus for microsurgery |
US5328481A (en) * | 1988-06-21 | 1994-07-12 | Alcon Laboratories, Inc. | Method for injecting viscous fluid into the eye to lift retinal membrane |
US4927676A (en) * | 1988-07-01 | 1990-05-22 | Becton, Dickinson And Company | Method for rapid adherence of endothelial cells onto a surface and surfaces prepared thereby |
US5308889A (en) * | 1988-11-21 | 1994-05-03 | Collagen Corporation | Dehydrated collagen-polymer strings |
US5292802A (en) * | 1988-11-21 | 1994-03-08 | Collagen Corporation | Collagen-polymer tubes for use in vascular surgery |
US5326584A (en) * | 1989-04-24 | 1994-07-05 | Drexel University | Biocompatible, surface modified materials and method of making the same |
US5962027A (en) * | 1989-08-14 | 1999-10-05 | Photogenesis, Inc. | Retinal cell transplant |
US5817075A (en) * | 1989-08-14 | 1998-10-06 | Photogenesis, Inc. | Method for preparation and transplantation of planar implants and surgical instrument therefor |
US6045791A (en) * | 1992-03-06 | 2000-04-04 | Photogenesis, Inc. | Retinal pigment epithelium transplantation |
US5324260A (en) * | 1992-04-27 | 1994-06-28 | Minnesota Mining And Manufacturing Company | Retrograde coronary sinus catheter |
US5326346A (en) * | 1992-07-27 | 1994-07-05 | Board Of Regents, The University Of Texas System | Light-cured urethane dimethacrylate ocular prosthesis |
US5323788A (en) * | 1992-09-21 | 1994-06-28 | Keravision | Overlapping split ring device for corneal curvature adjustment |
US5374515A (en) * | 1992-11-13 | 1994-12-20 | Organogenesis, Inc. | In vitro cornea equivalent model |
US5342370A (en) * | 1993-03-19 | 1994-08-30 | University Of Miami | Method and apparatus for implanting an artifical meshwork in glaucoma surgery |
US5582617A (en) * | 1993-07-21 | 1996-12-10 | Charles H. Klieman | Surgical instrument for endoscopic and general surgery |
US5339723A (en) * | 1993-09-30 | 1994-08-23 | Ethicon, Inc. | Pressurized fluid actuation system for amplifying operator input force in a surgical instrument |
US5533981A (en) * | 1994-10-06 | 1996-07-09 | Baxter International Inc. | Syringe infusion pump having a syringe plunger sensor |
US5720742A (en) * | 1994-10-11 | 1998-02-24 | Zacharias; Jaime | Controller and actuating system for surgical instrument |
US6036678A (en) * | 1995-02-28 | 2000-03-14 | Photogenesis, Inc. | Method for preparation and transplantation of planar implants and surgical instrument therefor |
US5868728A (en) * | 1995-02-28 | 1999-02-09 | Photogenesis, Inc. | Medical linear actuator for surgical delivery, manipulation, and extraction |
US5993474A (en) * | 1996-06-11 | 1999-11-30 | Asahi Kogaku Kogyo Kabushiki Kaisha | Treatment accessory for endoscope |
US5941250A (en) * | 1996-11-21 | 1999-08-24 | University Of Louisville Research Foundation Inc. | Retinal tissue implantation method |
US6156042A (en) * | 1997-11-17 | 2000-12-05 | Aramant; Robert B. | Retinal tissue implantation instrument |
US6159218A (en) * | 1999-05-19 | 2000-12-12 | Aramant; Robert B. | Retinal tissue implantation tool |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100191103A1 (en) * | 2002-09-17 | 2010-07-29 | Iscience Interventional Corporation | Apparatus and method for surgical bypass of aqueous humor |
US20090043321A1 (en) * | 2004-04-29 | 2009-02-12 | Iscience Interventional Corporation | Apparatus And Method For Surgical Enhancement Of Aqueous Humor Drainage |
US20100173866A1 (en) * | 2004-04-29 | 2010-07-08 | Iscience Interventional Corporation | Apparatus and method for ocular treatment |
US20070179512A1 (en) * | 2006-01-31 | 2007-08-02 | Olsen Timothy W | Surgical support structure |
US10278808B2 (en) | 2006-01-31 | 2019-05-07 | Emory University | Surgical support structure |
JP2013230391A (en) * | 2007-03-28 | 2013-11-14 | Revision Optics Inc | Insertion system for corneal implants |
US20100191177A1 (en) * | 2009-01-23 | 2010-07-29 | Iscience Interventional Corporation | Device for aspirating fluids |
US8425473B2 (en) | 2009-01-23 | 2013-04-23 | Iscience Interventional Corporation | Subretinal access device |
US20100241060A1 (en) * | 2009-03-18 | 2010-09-23 | Roizman Keith | Surgical devices and methods |
Also Published As
Publication number | Publication date |
---|---|
US5962027A (en) | 1999-10-05 |
US20030104618A1 (en) | 2003-06-05 |
US6579256B2 (en) | 2003-06-17 |
US6955809B2 (en) | 2005-10-18 |
SG49267A1 (en) | 1998-05-18 |
US20020055724A1 (en) | 2002-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6955809B2 (en) | Retinal cell grafts | |
US6514238B1 (en) | Method for preparation and transplantation of volute grafts and surgical instrument therefor | |
CA2158443C (en) | Method for preparation and transplantation of volute grafts and surgical instrument therefor | |
EP0486589B1 (en) | Surgical instrument and cell isolation | |
US5817075A (en) | Method for preparation and transplantation of planar implants and surgical instrument therefor | |
Silverman et al. | Transplantation of photoreceptors to light-damaged retina. | |
Morihisa et al. | Adrenal medulla grafts survice and exhibit catecholamine-specific fluorescence in the primate brain | |
da Cruz et al. | RPE transplantation and its role in retinal disease | |
Wongpichedchai et al. | Comparison of external and internal approaches for transplantation of autologous retinal pigment epithelium. | |
JP3490447B2 (en) | Retinal pigment epithelium transplantation | |
Huang et al. | Preparation and transplantation of photoreceptor sheets | |
Rothstein | Experimental techniques for investigation of the amphibian lens epithelium | |
del Cerro et al. | Retinal transplants into adult eyes affected by phototoxic retinopathy | |
AU716820B2 (en) | Method for preparation and transplantation of volute grafts and surgical instrument therefor | |
TW524681B (en) | Volute grafts and method for preparing the same | |
Palanker | Transplantation of Photoreceptors for Restoration of Sight | |
ROTHSTEIN | Experimental Techniqueſ for Inveſtigation of the Amphibian Lem'ſ Epithelium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |